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Human papillomavirus (HPV) is the most common sexually transmitted infection and the 
leading cause of cervical cancer in the United States. Women from racial and ethnic 
minorities with genital HPV are 2 to 3 times more likely to develop cervical cancer. 
Vaccines are currently available to prevent HPV infections; however, despite their 
effectiveness, national completion rates for these vaccines remain low among Hispanic 
adolescents compared to non-Hispanic White adolescents. The reasons for this 
racial/ethnic disparity are not fully understood. In this quantitative, cross-sectional study, 
which was guided by the socioecological framework, the extent to which insurance 
coverage and having a source of health care influenced completion of the HPV vaccine 
series among Hispanic adolescent girls was examined. Nationally representative data 
from the 2016 National Immunization Survey-Teen was analyzed. Results of multiple 
logistic regression showed that gaps in insurance coverage did not adversely affect 
completing the HPV vaccine series. Hispanic girls with continuous health insurance 
coverage (p < .001) and girls who experienced gaps in health insurance coverage (p < 
.001) were significantly more likely to complete the HPV vaccine series compared to 
Hispanic girls who were uninsured. These results can be used to guide effective strategies 
to increase HPV vaccination among Hispanic adolescents. Increasing the HPV vaccine 
series completion rate among Hispanic adolescents has important implications for 
positive social change, including decreasing their risk of infections, reducing the 
prevalence of cervical cancers later in life, and decreasing the economic burden 
associated with HPV infections among Hispanic women. 
 
 
Insurance Coverage and Completion of Human Papillomavirus Vaccine Series Among 
Hispanic Girls 
by 
Adrienne A. Scott 
 




Dissertation Submitted in Partial Fulfillment 
of the Requirements for the Degree of 









I dedicate this dissertation to my mother, Luceva V. McKoy, and sister, Janet C. 
Scott. You are always loved, never forgotten, and missed beyond measure. Your lives 




All praise and thanks to the Lord God Almighty, with whom any thing is possible. 
It is by His grace that I completed this study/doctoral program. 
I would like to extend my sincere thanks and appreciation to Dr. Newell and Dr. 
Nyanzi, the members of my dissertation committee, for their guidance, insightful 
comments, and support of my study. I would especially like to thank Dr. Rangel, the 
chair of my committee. Dr. Rangel, it was an honor and a privilege working with you. 
Thanks for your continuous support, your patience, and your invaluable insight into the 
development and completion of this study.  
I am deeply indebted to my family, without whom completion of this doctoral 
program would not have been possible. Thanks for your unwavering support, 
encouragement, and profound belief in my abilities. I am extremely grateful to my friends 
and colleagues, Tracy Solomon, Alicia Mingo, and Robson Chagas. Tracy Solomon, 
thank you for introducing me to Walden University and for instigating my enrollment in 
the doctoral program. Alicia Mingo, I could not have asked for a better friend to 
accompany me on this journey; your unrelenting and unparalleled determination inspired 
me. Robson Chagas, thank you for your invaluable contribution to this study. I would 
also like to extend my gratitude to all my other friends, who are too numerous to mention 
by name. Your encouragement throughout the dissertation process is priceless. Thanks a 
million for supporting me on this journey. Lastly, I extend a special thank you to the 
editors, statisticians, and staff members whose invaluable insight was instrumental to the 
completion of this study.  
 
i 
Table of Contents 
List of Tables ............................................................................................................... vi 
List of Figures ............................................................................................................. vii 
Chapter 1: Introduction to the Study ................................................................................... 1 
Introduction ................................................................................................................... 1 
Background of the Study .............................................................................................. 5 
Problem Statement ........................................................................................................ 8 
Purpose of the Study ................................................................................................... 10 
Research Questions and Hypotheses .......................................................................... 10 
Theoretical Background .............................................................................................. 12 
Nature of the Study ..................................................................................................... 15 
Operational Definitions ............................................................................................... 16 
Assumptions of the Study ........................................................................................... 16 
Scope and Delimitations ............................................................................................. 17 
Limitations of the Study.............................................................................................. 17 
Significance of the Study ............................................................................................ 17 
Summary ..................................................................................................................... 18 
Chapter 2: Literature Review ............................................................................................ 20 
Introduction ................................................................................................................. 20 
Literature Search Strategy........................................................................................... 21 
Theoretical Foundation ............................................................................................... 22 
Socioecological Model.......................................................................................... 22 
 
ii 
Justification for Using the Socioecological Model ............................................... 27 
Literature Review Related to Key Variables and Concepts ........................................ 30 
Overview of HPV ................................................................................................. 30 
HPV-Related Cancers ........................................................................................... 31 
HPV Vaccine ........................................................................................................ 33 
Individual and Contextual Factors That Influence HPV Vaccination ........................ 37 
Age and Gender .................................................................................................... 38 
Race and Ethnicity ................................................................................................ 40 
Country of Birth .................................................................................................... 40 
Perceptions of the HPV Vaccine................................................................................. 42 
Maternal-Related Factors ...................................................................................... 42 
Adolescent Perceptions About the Vaccine .......................................................... 44 
Provider Recommendation.......................................................................................... 45 
Financial Barriers ........................................................................................................ 47 
Cost of the Vaccine ............................................................................................... 47 
Health Care Providers’ Administrative Fees ........................................................ 48 
Socioeconomic Status ........................................................................................... 49 
Hispanics and the Risk of HPV .................................................................................. 51 
Hispanic Health ..................................................................................................... 51 
HPV Among Hispanics ......................................................................................... 53 
Acculturation, Health Literacy, Social Influence, and HPV Vaccination ............ 54 
Access to Health Care and HPV Vaccination ............................................................. 57 
 
iii 
Insurance Coverage and HPV Vaccination ................................................................. 60 
Summary ..................................................................................................................... 64 
Chapter 3: Research Method ............................................................................................. 66 
Introduction ................................................................................................................. 66 
Research Design and Rationale .................................................................................. 67 
Methodology ............................................................................................................... 68 
Target Population .................................................................................................. 68 
Sampling and Sampling Procedure ....................................................................... 68 
Sample Size and Power ......................................................................................... 71 
Access to the Data Set................................................................................................. 72 
Instrumentation ........................................................................................................... 73 
Operationalization of Constructs ................................................................................ 74 
Data Analysis Plan ...................................................................................................... 75 
Research Question 1 ............................................................................................. 76 
Research Question 2 ............................................................................................. 77 
Research Question 3 ............................................................................................. 79 
Statistical Assumptions: Chi-Square Test ............................................................. 81 
Statistical Assumptions: Multivariate Logistic Regression .................................. 82 
Rationale for Inclusion of Covariates ................................................................... 83 
Threats to Validity ...................................................................................................... 84 
External Validity ................................................................................................... 84 
Internal Validity .................................................................................................... 84 
 
iv 
Construct Validity ................................................................................................. 85 
Ethical Considerations ................................................................................................ 86 
Summary ..................................................................................................................... 87 
Chapter 4: Results ............................................................................................................. 88 
Introduction ................................................................................................................. 88 
Survey Response Rates ............................................................................................... 88 
Representativeness of the Sample ............................................................................... 88 
Discrepancies in Data Collection ................................................................................ 89 
Results ......................................................................................................................... 89 
Descriptive Characteristics of the Study Sample .................................................. 89 
Bivariate Analysis ................................................................................................. 92 
Research Question 1 and Hypotheses ................................................................... 93 
Research Question 2 and Hypotheses ................................................................... 98 
Research Question 3 and Hypotheses ................................................................. 100 
Summary ................................................................................................................... 105 
Chapter 5: Discussion, Recommendations, and Conclusion .......................................... 107 
Introduction ............................................................................................................... 107 
Interpretation of the Findings.................................................................................... 108 
Limitations of the Study............................................................................................ 114 
Recommendations for Future Studies ....................................................................... 114 
Implications for Positive Social Change ................................................................... 115 
Conclusion ................................................................................................................ 116 
 
v 




List of Tables 
Table 1. Descriptive and Demographic Characteristics of the Study Sample .................. 91 
Table 2. Contingency Table for Health Insurance Coverage and HPV Vaccination ........ 92 
Table 3. Contingency Table for Continuity in Health Insurance Coverage and HPV 
Vaccination ........................................................................................................... 93 
Table 4. Contingency Table for Type of Medical Facility Used to Access Care and    
HPV Vaccination .................................................................................................. 93 
Table 5. Logistic Regression Results for Completing HPV Vaccine Series Based on 
Health Insurance Coverage ................................................................................... 95 
Table 6. Logistic Regression Results for Completing HPV Vaccine Series Based on 
Continuity in Health Insurance Coverage ............................................................. 98 
Table 7. Logistic Regression Results for Completing HPV Vaccine Series Based on  
Type of Medical Facility Used to Access Health Care ....................................... 100 
Table 8. Logistic Regression Results for HPV Vaccination Based on Discontinuity in 
Health Insurance Coverage and Type of Medical Facility Used to Access     
Health Care ......................................................................................................... 103 
Table 9. Logistic Regression Results for HPV Vaccination Based on Discontinuity in 
Health Insurance Coverage and Type of Medical Facility Used to Access     





List of Figures 
Figure 1. Socioecological model....................................................................................... 13 
Figure 2. Socioecological framework for HPV vaccine uptake. ...................................... 15 




Chapter 1: Introduction to the Study  
Introduction 
 In the United States, genital human papillomavirus (HPV) is the most common 
sexually transmitted infection (STI) affecting men and women (Centers for Disease 
Control and Prevention [CDC], 2017). The infection is so common that individuals who 
are sexually active have a 75% chance of being infected with HPV at some point in their 
lifetimes (CDC, 2017; Tota, Chevarie-Davis, Richardson, DeVries, & Franco, 2011; 
Valentino & Poronsky, 2016). In the United States alone, approximately 80 million 
people are infected with HPV, and each year, 14 million newly infected cases are 
diagnosed, with 50% of the cases occurring in persons 15 to 24 years of age (CDC, 2017; 
Tota et al., 2011; Valentino & Poronsky, 2016).  
 In most cases, the infection is cleared within 2 years by the body’s immune 
system, but persistent infection with high-risk HPV serotypes (e.g., HPV 16 and 18) can 
lead to cervical, anal, penile, vaginal, vulvar, and oropharyngeal cancers later in life 
(CDC, 2017; Nickel et al., 2017; Pahud & Ault, 2015). Likewise, persistent infection 
with low-risk serotypes (e.g., HPV 6 and 11) can lead to the development of genital warts 
in adolescents (CDC, 2017; Nickel et al., 2017; Pahud & Ault, 2015). More than 33,000 
HPV-related cancers are diagnosed annually, and approximately 62% of these cases are 
among women (CDC, 2017; Lai et al., 2017; Markowitz et al., 2014). Moreover, 70% of 
cervical cancers and 90% of genital warts in women are HPV related (CDC, 2017).  
 Prior to 2006, prevention of cervical cancer was limited to secondary preventative 
measures like early detection with the Papanicolau (Pap) test (González, Suárez, & Ortiz, 
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2015; Thomas, 2016). The Pap test is a safe, noninvasive, and inexpensive procedure 
used for detecting abnormal cells that might lead to cancer if left untreated; however, 
most women who are diagnosed with cervical cancer have never been screened for the 
disease (Glick, Clarke, Blanchard, & Whitaker, 2012; McKeever, Bloch, & Marrell, 
2015). In the United States, racial and ethnic minority women and women from a lower 
socioeconomic status are 2 to 3 times more likely to develop cervical cancer because of 
persistent infection with genital HPV and are less likely to have a Pap test (American 
Cancer Society [ACS], 2017; Lechuga, Vera-Cala, & Martinez-Donate, 2016). For 
example, even though Hispanic women tend to have a higher incidence of cervical 
cancer, they are less likely to be screened for HPV-related cancers compared to African 
Americans and other non-Hispanic women (ACS, 2017; Lechuga et al., 2016; Roncancio, 
Ward, Carmack, Muñoz, & Cribbs, 2017). In fact, each year, approximately 2,000 
Hispanic women are diagnosed with cervical cancer, and about 600 of them die from the 
disease (ACS, 2017).  
 Three vaccines against HPV are currently available, and although these vaccines 
do not treat existing infection, they are effective in preventing vaccine-specific HPV 
infections in adolescents and young adults (CDC, 2017; Dunne et al., 2014; Markowitz et 
al., 2014; Yang, Farmer, Wu, & Hung, 2016). To harness the full potential of these 
vaccines, all recommended doses should be administered before exposure to HPV (i.e., 
before engaging in sexual intercourse; Markowitz et al., 2014; Tota et al., 2011; 
Valentino & Poronsky, 2016). Receipt of the vaccine series before sexual debut is 
imperative because it is estimated that vaccinating young girls not only reduces the 
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prevalence of HPV by 64% but also can reduce the incidence of cervical cancer by 
greater than 90% (Markowitz et al., 2016; Roncancio et al., 2016). Per the Advisory 
Committee for Immunization Practice (ACIP), girls as young as 9 years of age through to 
12 years of age should be vaccinated against HPV (CDC, 2017; Markowitz et al., 2014).  
 Three doses of the vaccine are recommended as a routine vaccination for girls 11 
to 12 years of age (CDC, 2017). For individuals 13 to 26 years of age who have not been 
vaccinated or who have not completed the vaccine series, catch-up vaccination is 
recommended (CDC, 2017). However, despite the effectiveness of the vaccines and the 
ACIP’s recommendation for HPV vaccination, national rates of completing the vaccine 
series remain low (CDC, 2017; Markowitz et al., 2014). Nationally, less than 50% of 
adolescent girls 13 to 17 years of age had received all three doses of the vaccine (CDC, 
2017; Markowitz et al., 2014).  
The percentage of adolescent girls who have completed the vaccine series varies 
by state, and from one state to another, this percentage has tended to be much lower 
among racial/ethnic minority girls (Jeudin, Liveright, del Carmen, & Perkins, 2014; 
Markowitz et al., 2014; Thompson, Rosen, Vamos, Kadono, & Daley, 2017). Adolescent 
Hispanic girls have higher rates than non-Hispanic White girls of initiating the vaccine 
series (Kepka, Ding, Bodson, Warner, & Mooney, 2015; Roncancio et al., 2017; Walker 
et al., 2017). However, Hispanic girls are less likely than non-Hispanic Whites or girls 
from other racial and ethnic minority groups to complete the vaccine series (Kepka, Ding, 
Bodson, Warner, & Mooney, 2015; Roncancio et al., 2017; Walker et al., 2017). 
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 Although completing the vaccine series is crucial for all girls (CDC, 2017; Kepka 
et al., 2015), it is more important for Hispanic girls, given the high incidence of cervical 
cancer in this population (Kepka et al., 2015). However, administering the vaccine to 
racial and ethnic minorities could be challenging because these adolescents are less likely 
to have access to preventive care services and are more likely to receive low-quality 
health care (Gelman et al., 2013; Polonijo & Carpiano, 2013). They are also less likely to 
have permanent medical homes and are more likely to be underinsured or uninsured 
(Jarlenski, Baller, Borrero, & Bennett, 2016; G. K. Singh, Rodriguez-Lainz, & Kogan, 
2013). Adolescents from racial and ethnic minority groups are also less likely to have at 
least one well-care visit per year (Gelman et al., 2013; Velasco-Mondragon, Jimenez, 
Palladino-Davis, Davis, & Escamilla-Cejudo, 2016). Because health care providers must 
administer the vaccine, having limited access to preventive services might prevent 
minority girls from completing the vaccine series.  
 I undertook this study to assess the extent to which having continuous health 
insurance coverage as well as a source of health care influenced completion of the HPV 
vaccine series among Hispanic female adolescents. Relative to the study, the implications 
for positive social change include informing guidelines and public health policies that 
support continuous access to preventive care services, regardless of insurance status. 
Reducing disparities in insurance coverage also could help to increase the uptake and 
completion of the HPV vaccine series among Hispanic adolescent girls. Boosting the 
completion rate of the vaccine series has the potential to reduce the risk of HPV infection 
among adolescent girls who are sexually active. Ultimately, there is the potential to 
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reduce the prevalence of HPV-related cervical cancer, which could then decrease the 
economic burden associated with HPV infection among Hispanic women. 
 Included this chapter is a summary of the literature pertaining to the current study, 
the research problem that was addressed, the purpose and nature of the study, and the 
research questions and hypotheses that guided this study. In this chapter, I will also 
provide the theoretical framework or conceptual foundation of the study; definitions of 
key terms and concepts related to the study; the limitations, scope, delimitations, and 
assumptions of the study; and the significance of the study. The chapter closes with a 
summary of the key points made in the chapter and a transition to Chapter 2.   
Background of the Study 
 Prevalence of HPV infection tends to peak shortly after the onset of sexual 
activity (CDC, 2017; Pahud & Ault, 2015). Comparatively, this prevalence correlates 
with the rate of infection among adolescent girls and young female adults, who tend to 
have a disproportionately higher rate of infection than women in other age groups (Bosch 
et al., 2013; Gamble, Klosky, Parra, & Randolph, 2010; Valentino & Poronsky, 2016). 
Most HPV infections are asymptomatic (Pahud & Ault, 2015). In 90% of HPV infections, 
the infection is resolved by the immune system within 2 years (Guerra-Rodríguez, 
Champion, Morano-Monsivais, Olivares-Ornelas, & Vazquez, 2017; Pahud & Ault, 
2015). For the remaining 10% of HPV infections, the infection will persist and can result 
in the development of HPV-related cervical cancer or genital warts (Cokkinides, Bandi, 
Siegel, & Jemal, 2012; Valentino & Poronsky, 2016).  
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 Despite the effectiveness of the vaccines in preventing HPV infection, Hispanic 
girls are less likely than non-Hispanic White girls or girls from other racial and ethnic 
minority groups to complete the HPV vaccine series (Kepka et al., 2015; Roncancio et 
al., 2017; Walker et al., 2017). Data from a 2014 national survey showed that among 
Hispanic adolescents, 66.3% of girls initiated the series but only 48.3% completed the 
three-dose series (Jemal et al., 2013). At the state level, the HPV vaccine initiation rate 
among Hispanic girls 13 to 17 years of age living in Texas has been reported as 55%, 
with only 39.3% completing the series (Jemal et al., 2013). Despite having higher rates of 
initiating the vaccine series, adolescent girls from racial and ethnic minority groups (e.g., 
Blacks and Latinas), from low-income families, and who are publicly insured have been 
shown to be consistently less likely to complete the vaccine series when compared to 
their affluent and privately insured White counterparts (Chou, Krill, Horton, Barat, & 
Trimble, 2011; Jeudin et al., 2014; Niccolai, Mehta, & Hadler, 2011).  
 As the primary caregivers, Hispanic mothers are likely to have their daughter(s) 
vaccinated against HPV if they perceive that the vaccine is beneficial, safe, and 
affordable, and if their health care providers recommend the vaccine series (Ashting, 
Chávez, & Serrano, 2016; Berenson, 2015; Brown, Gabra, & Pellman, 2017). Gaining 
consent from the mothers is crucial to the likelihood of their daughters completing the 
vaccine series (Ferrer, Trotter, Hickman, & Audrey, 2014). However, the mothers’ 
consent is dependent on other factors, such as characteristics of the subjects in question 
(i.e., girls’ ages); concerns that the vaccine promotes sexual promiscuity; and awareness 
and knowledge of HPV, the vaccines, and HPV-related diseases (Dorell, Yankey, 
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Santibanez, & Markowitz, 2011; Ferrer et al., 2014; Laz, Rahman, & Berenson, 2012; 
Perkins, Brogly, Adams, & Freund, 2012; Thompson, Best, Vamos, & Daley, 2017). 
Other factors, such as being able to afford the vaccine, having health insurance, and 
having access to preventive services, also can affect the likelihood of daughters 
completing the vaccine series (Gerend, Zapata, & Reyes, 2013; Roncancio et al., 2016, 
2017). However, there continues to be a lack of knowledge about the impact of insurance 
coverage and accessibility of preventive services on completing the HPV vaccine series. I 
filled a gap in the literature with this study by assessing the ways that continuity in 
insurance coverage and access to preventive services influenced completion of the HPV 
vaccine series among Hispanic girls.  
 Hispanics encounter many challenges that shape the conditions in which they live 
and affect their overall health and well-being (Velasco-Mondragon et al., 2016). They are 
more susceptible to being less educated, having limited access to health care services, 
having a lower socioeconomic status, and being underinsured (Velasco-Mondragon et al., 
2016). Subsequently, Hispanic adolescents living in certain communities across the 
United States might be misinformed about the efficacy and safety of the HPV vaccines 
and might have limited access to preventive care services (Katz et al., 2016). Relative to 
the cost of the vaccine, these individuals might not have insurance and might not know 
about the Vaccine for Children Program, which provides the vaccine at no cost to 




  Racial and ethnic disparities in HPV vaccination are likely due to a combination 
of different factors. Disparities in insurance coverage have been shown to affect access to 
and utilization of health care and also might be contributing to disparities in the health of 
Hispanic children (DeCamp & Bundy, 2012). Efforts have been made over the years to 
increase insurance coverage and to make health care more accessible to Hispanics 
(DeCamp & Bundy, 2012). However, many eligible Hispanic adolescents are less likely 
to be enrolled, and if enrolled, they are more likely to experience the effects of 
discontinuity in health insurance coverage (DeCamp & Bundy, 2012; DeVoe, Tillotson, 
Angier, & Wallace, 2015; Gelman et al., 2013).  
Insurance coverage is crucial to the uptake of the vaccine because research has 
shown that initiation of the vaccine series is the lowest among girls who are uninsured 
(Reiter et al., 2014), yet very little is known about the impact of discontinuous insurance 
coverage on completing the HPV vaccine series. The HPV vaccine is administered over a 
6-month period: baseline (0 months), 2 months, and 6 months; however, not everyone 
follows this schedule (Widdice, Bernstein, Leonard, Marsolo, & Kahn, 2011). Some girls 
might take longer to complete the vaccine series. During this time, individuals’ insurance 
status might change (e.g., they might be without health insurance for a period of time, 
making it unlikely that they will complete the vaccine series; Cowburn, Carlson, & 
Lapidus, 2014). Few researchers have investigated the association between insurance 
continuity and completion of the vaccine series, and studies assessing the relationship 
between insurance coverage and completion of the vaccine series have yielded mixed 
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results (Cowburn et al., 2014; Federico, Abrams, Everhart, Melinkovich, & Hambridge, 
2010; Tiro et al., 2012). The results of these studies were inconclusive and were further 
complicated by differences in how insurance status was measured. Furthermore, most 
researchers have tended to assess insurance coverage at a single point in time (Cowburn 
et al., 2014; Federico et al., 2010; Tiro et al., 2012). The issue with measuring insurance 
coverage at a single point in time is that it is difficult to assess how lapses in insurance 
coverage affect completing the vaccine series.  
With this study, I sought to assess the influence of insurance coverage on HPV 
vaccine rates for adolescents. More specifically, I explored the extent to which gaps in 
insurance coverage influenced completion of the vaccine series for a nationally 
representative sample of Hispanic adolescents. Because health insurance increases the 
likelihood of accessing different types of health care facilities, the impact of insurance 
coverage and source of health care on completion of the HPV vaccine series were also 
assessed.  
With programs like the Children Health Insurance Program, children can be 
insured regardless of the insurance status of their parents (DeVoe et al., 2016). However, 
although poorly understood, parental insurance coverage influences the likelihood of the 
children being continuously insured (DeVoe et al., 2015, 2016). Whether covered by 
private or public insurance, DeVoe et al. (2016) showed that the insured children of 
insured parents, in comparison to the insured children of uninsured parents, have a lower 
chance of experiencing gaps in insurance coverage. Understanding how fluctuations in 
insurance coverage affected the use of preventative services was important in identifying 
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new guidelines that can be implemented to boost HPV vaccination coverage among high-
risk populations.  
Purpose of the Study 
  The purpose of this quantitative study was to assess the relationship between 
discontinuity in insurance coverage, the type of medical facility used for health care, and 
HPV vaccination among Hispanic girls. The dependent variable in the study was HPV 
vaccination status (i.e., being fully vaccinated or not fully vaccinated), and the 
independent variables were insurance coverage (i.e., insurance status of the adolescent) 
and type of medical facility used to access health care. Covariates included maternal age, 
family income, maternal education, and health care provider recommendation to get the 
HPV vaccine series.  
 I measured the dependent variable, HPV vaccination status, as a dichotomous 
variable. The independent variables, insurance coverage and type of medical facility, 
were measured as nominal variables. The covariates, maternal age and family income, 
were measured as continuous variables; maternal education was measured as an ordinal 
variable; and health care provider recommendation was measured as a nominal variable. 
Research Questions and Hypotheses 
The study was guided by the following three research questions and the 
corresponding hypotheses: 
Research Question 1: Is there a statistically significant relationship between health 
insurance coverage and the HPV vaccination status of Hispanic girls?  
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H01: There is no statistically significant association between health insurance 
coverage and the HPV vaccination status of Hispanic girls.  
Ha1: There is a statistically significant association between health insurance 
coverage and the HPV vaccination status of Hispanic girls. 
Research Question 2: Is there a statistically significant relationship between the 
type of medical facility used to access health care and the HPV vaccination status of 
Hispanic girls?  
H02: There is no statistically significant association between the type of medical 
facility used to access health care and the HPV vaccination status of Hispanic girls.  
Ha2: There is a statistically significant association between the type of medical 
facility used to access health care and the HPV vaccination status of Hispanic girls. 
Research Question 3: Is there a statistically significant relationship between health 
insurance coverage, the type of medical facility used to access health care, and the 
likelihood of completing the HPV vaccine series?  
H03: There is no statistically significant association between health insurance 
coverage, the type of medical facility used to access health care, and the likelihood of 
completing the HPV vaccine series.  
Ha3: There is a statistically significant association between health insurance 
coverage, the type of medical facility used to access health care, and the likelihood of 




 I based this study on the tenets of the socioecological model (SEM), which was 
used to explain the relationship between individuals’ health and their environments. 
Based on the assumption that health is the result of several factors, the SEM theorizes 
that the social and physical environments, as well as organizational factors, policies, and 
regulations, interact to determine the health and health behaviors of individuals (Baral, 
Logie, Grosso, Wirtz, & Beyrer, 2013; Paat, 2013). The SEM is the culmination of the 
work of Bronfenbrenner (1977); McLeroy, Bibeau, Steckler, and Glanz (1988); Stokols 
(1992; and Stokols, Grzywacz, McMahan, & Phillips, 2003). Bronfenbrenner’s 
ecological systems theory emphasized the relationship between individuals and their 
environments; McLeroy et al.’s ecological model of health behaviors highlighted the 
different levels of influence on health behaviors; and the social ecological model of 
health promotion (Stokols, 1992; Stokols et al., 2003) outlined the assumptions that 
support the SEM (Baral et al., 2013; Nyambe, Van Hal, & Kampen, 2016).  
 As shown in Figure 1, the SEM is divided into five levels of influence that 
determine health outcomes or reduce risks to given health outcomes: (a) individual-
related factors or intrapersonal factors, (b) interpersonal factors, (c) organizational-related 
factors, (d) community-level factors, and (e) public policy-level factors (Baral et al., 
2013; Chimphamba-Gombachika et al., 2012). Individual-related factors are based on 
characteristics of the individual (i.e., beliefs, attitudes, and knowledge; Baral et al., 2013; 
Chimphamba-Gombachika et al., 2012). Interpersonal factors refer to individuals’ social 
groups or networks (i.e., family members, friends, spouses/partners, health care 
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providers; Baral et al., 2013; Chimphamba-Gombachika et al., 2012). Organizational-
related factors are formal or informal factors, such as rules and regulations, that regulate 
the operations of social institutions or organizations (Baral et al., 2013; Chimphamba-
Gombachika et al., 2012). Community-level factors relate to the relationships between 
and among different entities (i.e., local, state, national, and federal), and public policy-
level factors relate to national, state, and local health laws and policies (Baral et al., 2013; 




Figure 1. Socioecological model. Adapted with modifications from “The social 
ecological model: A framework for prevention,” by CDC, 2015a. Retrieved from 
http://www.cdc.gov/violenceprevention/overview/social-ecologicalmodel.html 
 I selected the SEM to understand the different determinants of a given health 
behavior, such as vaccine usage, and how these determinants interact to influence the 
decision to engage in such behavior. For example, as shown in Figure 2, Hispanic 
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mothers’ perceptions of the susceptibility of their children to HPV-related diseases, the 
barriers to accessing the vaccine, and the perceived benefits of the vaccine might 
influence their decision to vaccinate their children against HPV. Likewise, their decision 
to accept the HPV vaccine is shaped by their social networks, the recommendation of 
health care providers, accessibility of health care facilities used for HPV health-related 
issues, and the availability of the vaccine at these locations. The mothers’ decision to 
vaccinate their daughters against HPV also is affected by their perceptions of the risk of 
HPV based on community levels of the disease, the financial cost of obtaining the 
vaccine, health coverage, whether state policy mandates HPV vaccine for school entry, 
and whether state-level regulations support the availability of HPV-related educational 
materials that are culturally appropriate (Fernandez, Allen, Mistry, & Kahn, 2010; 






Figure 2. Socioecological framework for HPV vaccine uptake. Adapted with 
modifications from “Screening and Vaccination As Determined by the Social Ecological 
Model and the Theory of Triadic Influence: A Systematic Review,” by A. Nyambe et al., 
2016, BMC Public Health, 16, p. 1166. Copyright 2016 by the A. Nyambe et al. Adapted 
with permission. 
Nature of the Study 
 I employed a quantitative, cross-sectional design in this study. I analyzed 
secondary data from the 2016 National Immunization Survey-Teen (NIS-Teen; CDC, 
2016a) to assess the relationship between insurance coverage, the type of medical facility 
used to access health care, and completion of the HPV vaccine series among Hispanic 
girls. After downloading and cleaning the data, I used logistic regression to determine the 
significance of the relationship between health insurance coverage, the type of medical 
facility used to access health care, and completion of the HPV vaccine series among 




  Discontinuity in health insurance coverage: Having a lapse or disruption in 
insurance coverage. This includes individuals who are currently insured but were 
uninsured at some point, individuals who are currently uninsured but were insured at 
some point, and individuals who are currently insured and never uninsured (CDC, 
2016b). This definition also includes individuals who are currently uninsured and were 
never insured. 
 Insurance coverage: Having insurance coverage, whether private or public health 
insurance (CDC, 2016b).  
 Type of medical facility: The facility an individual used to access their primary 
care provider. This includes public health-operated clinics, hospital-based clinics, or 
private practice (CDC, 2016b).  
  Vaccination status: Whether girls are fully vaccinated with the recommended 
HPV vaccines (CDC, 2016b). A “no” response indicates that they were not vaccinated, 
and a “yes” response indicates that they had received at least one dose of the HPV 
vaccine series.  
Assumptions of the Study 
 I made several key assumptions in this study. The first assumption was that the 
instrument used to collect the data was valid and reliable based on its use in other HPV 
vaccination studies. Another assumption was that the collected data were free of any 
interviewer bias. I also assumed that the collected data were truthful based on the 
knowledge and ability of the respondents. 
17 
 
Scope and Delimitations 
  The focus of the study was on adolescent Hispanic girls, so the findings cannot 
be generalized to all adolescent girls. Relative to completing the vaccine series, I focused 
only on the HPV vaccine in girls in this study; therefore, the findings cannot be 
generalized to boys and other multidose vaccines. The collected data were limited to the 
responses given by the responding parents or guardians, who determined the eligibility of 
the adolescents present in the household and provided all information pertaining to the 
adolescents. The NIS-Teen collected data only on adolescents living in the United States 
and select territories at the time of the interview.  
Limitations of the Study 
  The study was subject to several limitations inherent in the use of secondary data. 
In using archival NIS-Teen data, this study was restricted to questions asked in the survey 
and was limited to the definitions, values, and nature of the variables in the NIS-Teen 
data set. The NIS-Teen data set contains provider-verified HPV vaccination information; 
however, self-reported demographics and other relevant information also might have led 
to an overestimation or underestimation of the variables in question. Given the propensity 
for bias with self-reported information, this bias could have affected the true nature of the 
relationship between these factors and completion of the HPV vaccine.  
Significance of the Study 
  The higher the rate of the HPV vaccine series completion is among adolescents, 
the more likely is the chance of reducing the risk of HPV-related disease later in 
adulthood (Wisk, Allchin, & Witt, 2014). Access to a source of health care and insurance 
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coverage are both integral to this process, so it was important that any potential barriers 
related to these constructs be identified and disseminated. Relative to positive social 
change, alleviating issues with the source of health care accessed and insurance coverage 
could help to increase the completion rate of the HPV vaccine series (Lu et al., 2018). In 
turn, boosting the vaccine series completion rate could reduce not only the risk of HPV-
related infection but also the prevalence of cervical cancer and, ultimately, decrease the 
economic burden associated with HPV infection among Hispanic women. 
Summary 
 In this chapter, I introduced insurance coverage, discontinuity in health insurance 
coverage, and source of health care as potential contributors to the disparity in 
completion of the HPV vaccine by adolescent Hispanic girls. Completing the HPV 
vaccine series is crucial for all girls, but for Hispanic girls, it is more important given the 
high incidence of cervical cancer among Hispanic female adults (Kepka et al., 2015). 
Administering the vaccine to adolescents from racial and ethnic minority groups is 
challenging because they are more likely to have limited access to preventive care 
services and be underinsured than to be continuously insured (Katz et al., 2016; Reiter et 
al., 2014). They also are less likely to have permanent medical homes and at least one 
well-care visit per year (Gelman et al., 2013; Velasco-Mondragon et al., 2016). Because 
health care providers are essential to administering the HPV vaccine series, discontinuous 
insurance coverage and limited access to a source of health care have the potential to 
interfere with completion of the vaccine series.  
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Employing a quantitative study design, I assessed the extent to which insurance 
coverage and the type of medical facility used to access health care affected the 
likelihood of Hispanic adolescent girls completing the HPV vaccine series in this study. 
Insurance coverage and having a source of health care might not resolve the issue of the 
underutilization of the HPV vaccine among Hispanic adolescents across the United 
States, but these constructs might help to highlight areas that can be targeted when 
formulating guidelines and policies that will aid in increasing the uptake of the HPV 
vaccine among this ethnic group. In Chapter 2, I will present a detailed discussion of the 
theoretical foundation of the study, the literature search strategy, and a review of the 
literature, with an emphasis on gaps in insurance coverage and immunizations among 
Hispanic girls living in the United States.  
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Chapter 2: Literature Review 
Introduction 
 Increasing the completion rate of the HPV vaccine series among adolescent girls 
has the potential to significantly reduce the prevalence and mortality rate of cervical 
cancer later in life (Valentino & Poronsky, 2016). Despite the effectiveness of the HPV 
vaccine and the ACIP’s recommendation for vaccinations (Fishman, Taylor, & Frank, 
2016; Vielot, Butler, Brookhart, Becker-Deps, & Smith, 2017), completion of the vaccine 
series continues to be low among adolescent girls. HPV vaccine completion among girls 
varies by age (Niccolai et al., 2011); state (Walker et al., 2017); race and ethnicity (Wisk 
et al., 2014); and socioeconomic status (Wisk et al., 2014). It also varies by insurance 
status and by the recommendation made, or not made, by health care providers to have 
the vaccine series (Gilkey et al., 2016; Jarlenski et al., 2016).  
 Completing this review of the literature was relevant to gaining a better 
understanding of the factors contributing to disparities in completing the HPV vaccine 
series. In Chapter 2, I provide an explanation of the ways that the SEM can be used as a 
framework to understand the reasons for the low completion rate of the HPV vaccine 
series. I present an overview of HPV, HPV-related diseases, and the HPV vaccines 
currently available to prevent HPV-related diseases. I also present a review of the 
literature relative to the continuity of insurance coverage and other barriers to the uptake 
of the vaccine. The chapter concludes with a discussion of the ways that gaps in 
insurance coverage and racial and ethnic disparities influence the uptake of the vaccine 
among Hispanic adolescent girls.  
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Literature Search Strategy 
 I conducted a comprehensive literature review to identify research on insurance 
continuity, HPV vaccine disparities, and racial and ethnic disparities and HPV vaccine 
completion among adolescents. The databases used in the search for relevant literature 
included Google Scholar, PubMed, MEDLINE, APA PsycNET, EBSCOhost, CINAHL, 
and Science Direct. I gathered additional resources from ProQuest Theses and 
Dissertations database and the U.S. National Library of Medicine. The key search terms 
used either in combination or isolation to locate peer-reviewed articles were insurance, 
insurance coverage, private insurance, public insurance, gaps in insurance, discontinuity 
in insurance, continuous insurance, vaccination, racial and ethnic minorities, human 
papillomavirus (HPV), HPV vaccine, HPV vaccination initiation and completion, HPV 
vaccine and insurance, vaccine-preventable diseases, cervical cancer prevention, Latino 
health, immigrants and HPV, immigrants’ health, African American health, HPV risk 
perception, health care facilities, preventive service, health care, well-care visit, provider 
recommendation, socioecological model, adolescents’ health, adolescents’ health 
disparity, and adolescents’ vaccines. Relative to this study, I set the limit to research 
articles published within the last 5 years in most databases, and as deemed necessary, I 
extended the limit to 10 years in other databases. I sought articles published between 10 
and 20 years ago based on their relevance to more recent literature and the current study. 
Relatedly, the number of publications addressing insurance coverage continuity as a 
factor in vaccination completion was limited; therefore, I expanded the scope of the 
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  This study was framed by the perspectives of the SEM, which is based on 
Bronfenbrenner’s (1977) ecological systems theory; McLeroy et al.’s (1988) ecological 
model of health behaviors; and the social ecological model of health promotion (Stokols, 
1992; Stokols et al., 2003). The SEM posits that five levels of influence determine 
behavior: (a) intrapersonal or individual characteristics such as beliefs, knowledge and, 
attitudes; (b) interpersonal factors; (c) organizational/institutional factors; (d) community-
related factors; and (e) societal level factors or public policies factors. (Baral et al., 2013; 
Chimphamba-Gombachika et al., 2012; Nyambe et al., 2016; Paat, 2013; Schölmerich & 
Kawachi, 2015). Figure 3 shows the interconnection between these factors and the ways 
that they influence each other to determine the uptake of the HPV vaccine (see Lanning, 





Figure 3. Socioecological model of factors influencing HPV vaccination. Adapted from 
“Improving Human Papillomavirus Vaccination Uptake Among College Students: A 
Socioecological Perspective,” by B. Lanning, M. Golman, & K. Crosslin, 2017, 
American Journal of Health Education, 48(2), p. 118. Copyright 2018 by Copyright 
Clearance Center. Adapted with permission. 
  Individual or intrapersonal factors are based on characteristics that influence 
given health behaviors. In this case, the characteristics of the mothers and the daughters 
affect completion of the HPV vaccine series (Fernandez et al., 2010; Ferrer, Audrey, 
Trotter, & Hickman, 2015). These characteristics include maternal acceptance of the 
vaccine and willingness to vaccinate their daughters against the virus (Fernandez et al., 
2010; Ferrer, Audrey, et al., 2015). Maternal acceptance of the vaccine depends on the 
mothers’ ages and beliefs, attitudes, and knowledge about HPV and the HPV vaccines 
(Fernandez et al., 2010; Ferrer, Audrey, et al., 2015). It also depends on maternal 
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socioeconomic status, educational attainment, level of health literacy, and level of 
acculturation if they are immigrants (Ciampa et al., 2012; Kepka et al., 2015; Walter, 
Murphy, Frank, & Baezconde-Garbanati, 2017; Wisk et al., 2014). As for adolescents, 
their ages, what they know about HPV and the vaccines, and whether their friends have 
or have not received the vaccine can influence their receipt of the vaccine (Fernandez et 
al., 2010; Ferrer, Audrey, et al., 2015). The decision to vaccinate or get the vaccine is 
also influenced by the risk perceptions of mothers and daughters, their perceptions of 
susceptibility to the infection, severity of the disease, and perceived benefits of the 
vaccine to protect against the infection or cervical cancer (Fernandez et al., 2010; C. E. 
Hansen, Credle, Shapiro, & Niccolai, 2016).  
 Interpersonal factors refer to the people in an individuals’ social networks or 
support groups who could influence receipt and completion of the vaccine series 
(Fernandez et al., 2010; Ferrer, Audrey, et al., 2015; Lanning et al., 2017). Among these 
sources of influence are family members, friends, health care providers, and spouses or 
partners (Lanning et al., 2017). Social influence is a known predictor of the uptake of the 
vaccine (Fernandez et al., 2010; Ferrer, Audrey, et al., 2015). For example, if mothers 
believe that their friends and family members approve of vaccinating young girls against 
HPV, they are more likely to have their daughters vaccinated against HPV (Fernandez et 
al., 2010; Ferrer, Audrey, et al., 2015). Likewise, if their health care providers 
recommend the vaccine, mothers are more likely to have their daughters vaccinated 
(Gilkey, Malo, Shah, Hall, & Brewer, 2015; Warner et al., 2017). Relative to the 
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daughters, if they perceive that their mothers approve of getting the vaccine, it will 
increase their chances of being vaccinated (Warner et al., 2017).  
 Organizational or institutional factors are formal or informal rules and regulations 
that regulate the availability of the HPV vaccine. In the United States, the U.S. Food and 
Drug Administration (FDA, 2018) approves the vaccine. The ACIP recommends the 
vaccine, decides who should be vaccinated, at what age, and how often the vaccine 
should be administered (CDC, 2016e). Vaccine manufacturers, commercial distributors, 
and state and local governments work together to develop or improve existing 
infrastructure to deliver the HPV vaccine series (Fernandez et al., 2010; Markowitz et al., 
2012; Shefer et al., 2012). Relative to the cost of the vaccine, public and private entities 
work together to make the vaccine more accessible (CDC, 2015b, 2018). However, at this 
level, the lack of an established adolescent vaccination program and the lack of a clear 
plan to maximize the uptake of the vaccine series also influence the HPV vaccine 
completion rate (Fernandez et al., 2010; Ferrer, Audrey, et al., 2015). 
 Community-level factors refer to local, state, national, and federal governing 
bodies that influence the uptake of the HPV vaccine. The cost of the vaccine affects its 
uptake (Fernandez et al., 2010; Ferrer, Trotter, Hickman, & Audrey, 2015; Warner et al., 
2017). The HPV vaccine is one of the most expensive vaccines available (CDC, 2015b, 
2018). For individuals with private or public insurance, the vaccine is covered by most 
private insurance plans and is available at no cost for individuals who are publicly 
insured; however, not all adolescents have private insurance or are eligible for federal or 
state-level programs that cover the cost of the vaccine (Lindley, Smith, & Rodewald, 
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2011). Also, not everyone without insurance can afford to pay for the vaccine themselves. 
Therefore, the lack of insurance and the lack of financial means to cover the cost of the 
vaccine mean that completion of the vaccine series is highly unlikely (Fernandez et al., 
2010; Ferrer, Trotter, et al., 2015). 
 The final level of influence encompasses public policies. These national, state, 
and local health laws and policies not only govern but also affect vaccine uptake. These 
policies include ordinances at the state and federal levels that make the vaccine 
mandatory for school entry or entrance into the United States (Fernandez et al., 2010). 
The policies also include mandates for increasing the availability of educational tools at 
clinics, schools, doctors’ offices, and so on (Fernandez et al., 2010). Raising awareness of 
and increasing knowledge about HPV and the HPV vaccines are instrumental to the 
receipt and completion of the vaccine series (Lai et al., 2017). However, making the 
vaccine mandatory is controversial, and only a few states have succeeded in making HPV 
vaccination mandatory for school entry (Fernandez et al., 2010). Mandating the vaccine 
for school entry could be more of a hindrance than a facilitator of the uptake of the 
vaccine (Fernandez et al., 2010).  
 Three groups of researchers have attempted to explain the uptake of the HPV 
vaccine using an integrated model based on the tenets of the SEM (Downs, Scarinci, 
Einstein, Collins, & Flowers, 2010; Fernandez et al., 2010; Ferrer et al., 2014). To 
identify the factors that inhibit or facilitate uptake of the HPV vaccine among young 
women, Ferrer et al. (2014) employed a systematic approach and found that parents, 
health care providers, and policymakers drove receipt of the HPV vaccine among young 
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women. Factors that negatively influenced the uptake of the vaccine included the cost of 
the vaccine, lack of health care provider recommendation, and cultural and religious 
values (Ferrer et al., 2014). Therefore, although health care providers and policymakers 
can have a positive effect on uptake of the vaccine, the lack of health care provider 
recommendations and religious values both can have a negative effect on the uptake of 
the vaccine. 
  To maximize the uptake of the HPV vaccine among high-risk adolescents, a 
multilevel approach is needed (Downs et al., 2010). According to Downs et al. (2010), 
this approach takes into consideration all levels of influence, beginning with individual-
related factors and continuing with factors related to social networks, organizational-
related factors, community, and public policies. Because this multilevel approach is more 
holistic, it is useful and more realistic as a foundation for improving uptake of the 
vaccine. Fernandez et al. (2010) also showed that personal as well as external factors, 
such as interpersonal, organizational, community and societal-related factors influence 
the intent to vaccinate against HPV as well as the acceptability of the vaccine. Moreover, 
Fernandez et al. posited that employing a multilevel approach to address issues with the 
uptake of the HPV vaccine series would likely enhance its uptake, unlike approaches that 
target a single factor like maternal attitudes.  
Justification for Using the Socioecological Model  
 The health belief model (HBM; Hochbaum, 1958; Rosenstock, Strecher, & 
Becker, 1988); the theory of planned behavior (TPB; Ajzen, 1991; Ajzen & Madden, 
1986); and the theory of reasoned action (TRA; Fishbein & Ajzen, 1977, 1980) are the 
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most commonly used theoretical approaches to explain behaviors among adolescents 
relevant to the HPV vaccine. However, the problem with the use of these models is that 
they capture only the psychological factors that affect the decision to accept the vaccine 
or the intent to have daughters vaccinated against HPV. The HBM, for example, offers 
six psychological factors that predict the likelihood of mothers allowing their daughters 
to be vaccinated against HPV: susceptibility to HPV (perceived susceptibility); severity 
of the disease (perceived severity); benefits of the vaccine (perceived benefits); barriers 
to obtaining the vaccine (perceived barriers); self-efficacy (i.e., mothers’ belief in their 
ability to act on information about the vaccine and HPV-related diseases); and call to 
action (i.e., having daughters complete the vaccine series; Bowyer, Forster, Marlow, & 
Waller, 2014; Morales-Campos, Markham, Peskin, & Fernandez, 2013; Spleen, 
Klushman, Clark, Dignan, & Lengerich, 2012). 
   The basic tenet of the TRA is that the intention to act on given cues is determined 
by behaviors (Fishbein & Ajzen, 1977, 1980). This intention is determined by two key 
elements, namely, attitudes toward the behaviors in question and subjective norms toward 
such behaviors (Fishbein & Ajzen, 1977, 1980). Subjective norms are individuals’ 
perceptions of what others think about their adopting the behaviors in question (Fishbein 
& Ajzen, 1977, 1980). Relative to HPV vaccination, researchers have used the TRA to 
predict or identify the factors that influence mothers’ intentions to have their daughters 
vaccinated against HPV (Natan, Aharon, Palickshvili, & Gurman, 2011; Reynolds & 
O’Connell, 2012) and to predict which elements influence health care providers to 
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recommend the HPV vaccine to the mothers of adolescent daughters (Roberto, Krieger, 
Katz, Goei, & Jain, 2011).   
   The TPB is an extension of the TRA (Ajzen, 1991; Ajzen & Madden, 1986). 
Because individuals might have little control over some behaviors, the TPB posits that 
individuals’ perceived control over given behaviors influences the intention to perform 
the behaviors in question (Ajzen, 1991; Ajzen & Madden, 1986). Concerning the HPV 
vaccine, researchers have used the TPB to assess mothers’ intentions to talk to their 
daughters about sex, HPV, and other HPV-related matters relative to the vaccine 
(Askelson et al., 2011b). It has been used to assess adolescents’ psychosocial factors that 
predict the likelihood of their being vaccinated against HPV (Bowyer et al., 2014) and to 
assess health care providers’ intentions to talk to young women about sex-related matters 
and the HPV vaccines (Askelson et al., 2011a). 
 Theories have been used to guide the development of interventions to maximize 
uptake of the HPV vaccine (Ferrer, Audrey, et al., 2015). As such, it was important to 
identify the most appropriate framework to guide such development. Although the 
constructs of the HBM have been used to explain why mothers are not complying with 
the recommendation to vaccinate their daughters against HPV, they have not been used to 
consider factors other than maternal-related perceptions that also could influence uptake 
of the HPV vaccine series (Ferrer, Audrey, et al., 2015). Similarly, even though the TRA 
and TPB have been used to understand the intentions of mothers, adolescent daughters, 
and physicians toward discussing HPV-related matters, they have failed to capture factors 
other than intention that could influence vaccinating young girls against HPV (Ferrer, 
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Audrey, et al., 2015). As established by the SEM, in addition to individual characteristics, 
family members, friends, policymakers, and societal and community-level factors are 
considered likely to influence uptake of the HPV vaccine (Lanning et al., 2017). 
According to Downs et al. (2010), this approach is more likely than approaches that 
target only the factors relating to the individuals to enhance uptake of the vaccine series.  
Literature Review Related to Key Variables and Concepts  
Overview of HPV  
 Genital HPV is the most common STI in the United States (CDC, 2017). The 
infection is so common that for persons who are sexually active, there is a 75% chance 
that they will be infected with at least one type of HPV at some point in life (CDC, 2017; 
Tota et al., 2011; Valentino & Poronsky, 2016). In the United States alone, approximately 
80 million people are infected with HPV, and each year, approximately 14 million newly 
infected cases are reported, with nearly 50% of the cases occurring in persons 15 to 24 
years of age (CDC, 2017; Tota et al., 2011; Valentino & Poronsky, 2016).  
 HPV is transmitted through genital contact and is directly transmitted from 
infected persons to their sexual partners. Transmission of HPV is not limited to vaginal 
intercourse; transmission also can occur during oral and anal sex (Valentino & Poronsky, 
2016). Because HPV is transmitted through sexual contact, the risk of infection is linked 
to sexual behaviors. Thus, the age when girls begin to engage in sexual activity, have 
multiple sexual partners, and not use condoms during sexual intercourse is associated 
with a higher risk of being infected with HPV (Chelimo, Wouldes, Cameron, & Elwood, 
2013; Valentino & Poronsky, 2016). Likewise, having a history of prior STIs and 
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engaging in nonmonogamous sexual relationships also are associated with a higher risk 
of being infected with HPV (Chelimo et al., 2013; Valentino & Poronsky, 2016). 
 More than 150 strains or serotypes of HPV have been identified, but only about 
40 of these serotypes are known to infect humans (CDC, 2017). Even though HPV 
infections are common, most infections occur without any symptoms and are cleared by 
the immune system within 2 years (CDC, 2017). As a result, most people are not aware 
of being infected with HPV and can easily spread the virus to their sexual partners 
without knowing it (CDC, 2017). Some infections can persist for years, and if left 
untreated, they might progress to cancer (CDC, 2017). Hence, sexually transmitted HPV 
serotypes are classified as low risk or high risk based on their cancer-causing potential 
(CDC, 2017).  
  Low-risk HPVs do not cause cancer, but they can cause warts on or around the 
genitals and anus (CDC, 2017). HPV Serotypes 6 and 11, for example, are low-risk 
serotypes associated with 90% of all genital warts (CDC, 2017). High-risk serotypes can 
cause cancer. There are several high-risk serotypes, but HPV Serotypes 16 and 18 are the 
most common and are associated with a high percentage of all HPV-related cancers 
(CDC, 2017). 
HPV-Related Cancers 
 According to CDC estimates, about 30,000 HPV-related cancers are diagnosed 
each year in the United States, with 63% of these cancers affecting women (as cited in 
McGhee et al., 2017). Of all HPV-related cancers, 87% of them are cancer of the cervix 
(Forman et al., 2012). In the United States, 70% of cervical cancers are HPV related; 
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each year, more than 12,820 new cases of cervical cancers are diagnosed, and of these 
cases, 4,000 will result in death (ACS, 2017).  
Compared to the high rate of HPV-related cervical cancer, the incidence of other 
HPV-related cancers remained relatively low for decades. However, in recent years, the 
frequency of these cancers has increased (Saslow et al., 2016). Sixty-nine percent of 
vulvar cancers, 75% of vaginal cancers, and 70% of oropharyngeal cancers are HPV 
related (CDC, 2017; McGhee et al., 2017; Saslow et al., 2016). Each year in the United 
States, 1,400 cases of vulvar cancer, 400 cases of vaginal cancers, and 7,000 cases of 
oropharyngeal cancers are diagnosed (McGhee et al., 2017). 
 Before 2006, prevention of cervical cancer was limited to secondary preventative 
measures such as screening and early detection with the Pap test (González et al., 2015; 
Thomas, 2016). The Pap test is a safe and noninvasive screening tool used to detect 
abnormal cells that might lead to cancer if left untreated. However, most women who are 
diagnosed with cervical cancer have never been screened for the disease (Glick et al., 
2012; McKeever et al., 2015). In the United States, women from racial and ethnic 
minority groups and women from a lower socioeconomic status are 2 to 3 times more 
likely to develop cervical cancer because of persistent infection with genital HPV and are 
less likely to have had a Pap test (ACS, 2017; Lechuga et al., 2016). For example, even 
though Hispanic women tend to have a higher incidence of cervical cancer, they are less 
likely than Blacks and other non-Hispanic White women to be screened for HPV-related 
cancers (ACS, 2017; Lechuga et al., 2016; Roncancio et al., 2017). Likewise, even 
though Blacks have the highest prevalence of HPV infections, they also are less likely to 
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be screened for HPV-related cancers (ACS, 2017; Lechuga et al., 2016; Roncancio et al., 
2017). 
 Cervical cancer is the only HPV-related cancer with guidelines for screening and 
a reliable test (CDC, 2016c). Hence, by adhering to screening guidelines, the incidence of 
cervical cancer is modifiable (CDC, 2016c). The availability of such guidelines and 
reliable tests for oropharyngeal, vaginal, and vulvar HPV-related cancers could help to 
reduce the rate (CDC, 2016c), but given the high frequency of these cancers, other 
measures should be employed to help to reduce their incidence (CDC, 2017; McGhee et 
al., 2017; Saslow et al., 2016). In these situations, a vaccine against HPV would be the 
most beneficial. Such a vaccine against HPV would not replace the Pap test or other 
screening tools, but it could help to reduce the incidence and mortality rate of HPV-
related cervical cancers. Similarly, a vaccine against HPV could help to reduce the 
prevalence of noncervical, HPV-related cancers (Jemal et al., 2013). 
HPV Vaccine 
   Before 2006, there were no vaccines to prevent or reduce the risk of HPV 
infection. In 2006, the FDA approved three vaccines against HPV infection (as cited in 
FDA, 2018). The first in the series of HPV vaccines to be approved in 2006 was a 
bivalent HPV vaccine (2vHPV). This vaccine protects against HPV Serotypes 16 and 18 
(Harper & DeMars, 2017). In 2009, the FDA approved a quadrivalent HPV vaccine 
(4vHPV). This vaccine targets HPV Serotypes 6, 11, 16 and 18 (Angioli et al., 2016). 
Finally, in 2014, a nine-valent vaccine (9vHPV) was introduced to the market. This 
vaccine targets HPV Serotypes 6, 11, 16 and 18 as well as 31, 33, 45, 52, and 58 (CDC, 
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2017; Draper et al., 2013). All three vaccines were designed to prevent infections with 
HPV Serotypes 16 and 18, the most common serotypes causing cancer. In addition, 
4vHPV targets HPV Serotypes 6 and 11, both of which are responsible for 90% of genital 
warts, and 9vHPV targets five other high-risk HPV serotypes (CDC, 2017).  
 The HPV vaccine stimulates the immune system to produce antibodies that are 
protective against vaccine-related HPV serotypes (Harper & DeMars, 2017). 
Comparative analysis of clinical studies supporting the approval of HPV vaccines 
indicated that antibodies against 2vHPV and 4vHPV provided protection against 90% to 
100% of infection caused by HPV Serotypes 16 and 18 (Einstein et al., 2011a, 2011b; 
Einstein, Levin, et al., 2014; Einstein, Takacs, et al., 2014). HPV vaccines also prevent 
the formation of precancerous cervical lesions or the transformation of cervical cell 
associated with persistent infection with HPV Serotypes 16 and 18 (Einstein et al., 2011a, 
2011b; Einstein, Levin, et al., 2014; Einstein, Takacs, et al., 2014). In addition, 2vHPV 
and 4vHPV have been found protective against HPV infection in other body sites. 
Antibodies against 2vHPV have reduced the number of vulvar HPV infection in young 
girls by 50%, and antibodies against 4vHPV have prevented 100% of vulvar and vaginal 
lesions caused by HPV infection (Kreimer et al., 2011).  
 In similar studies, 9vHPV antibodies have been shown to protect against infection 
caused by all nine vaccine-related serotypes in all study participants (Joura et al., 2015). 
Furthermore, researchers have estimated that by including five additional high-risk 
serotypes in the 9vHPV vaccine, the vaccine has the potential to prevent more than 90% 
of cervical cancer (De Sanjosé et al., 2010; Joura et al., 2014; Serrano et al., 2012). 
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Overall, the HPV vaccines are protective against infections caused by the serotypes of 
HPV included in them and they have the potential to reduce the incidence of HPV-related 
cancers caused by these serotypes. 
 A vaccine’s effectiveness is assessed by how efficiently it is taken up by the 
population and the level of protection that it subsequently provides through what is called 
herd immunity (Kahn et al., 2012). Seven years after the introduction of the HPV 
vaccines, Drolet et al. (2015) noted that when vaccine coverage rate exceeded 50%, the 
vaccine significantly reduced the prevalence of HPV at the population level. This result 
suggested that with higher rates of completion, the prevalence of HPV infection has 
become lower, which means more protection for individuals who are unvaccinated 
against HPV (Drolet et al., 2015; Harper & DeMars, 2017). The current study supports 
not only the importance of being vaccinated against HPV but also the need to improve 
the rate of completing the vaccine series within the specified time frame.  
 Markowitz et al. (2016) provided additional evidence supporting the efficacy of 
the vaccine. Using data from the National Health and Nutrition Examination Survey, 
these researchers demonstrated that the HPV vaccine significantly reduced the prevalence 
of HPV infection among adolescent girls. Because the vaccine was not approved until 
late 2006, the researchers used data from 2003 to 2006 to represent the time before the 
vaccine and data from 2009 to 2012 to represent the time after the vaccine. Participants 
whose HPV status was determined by HPV genotyping were interviewed during each 
time frame. The genotyping was included in their analysis.  
36 
 
Markowitz et al. (2016) found among girls 14 to 19 years of age, the incidence of 
HPV infection caused by HPV Serotypes 6, 11, 16 and 18 was reduced by 64%, that is, 
from 11.5% prevaccine to 4.3% postvaccination. They also noticed a 34% reduction in 
HPV prevalence among participants 20 to 24 years of age. For HPV 16 and 18 alone, 
they observed a 50% reduction in infection caused by these two high-risk serotypes. Even 
with the low number of participants who completed the three-dose vaccine series, their 
results showed that the HPV vaccine was highly effective in preventing HPV infection 
and that over time, this reduction in the incidence of vaccine-type HPV serotypes could 
reduce cervical cancer and other HPV-related cancers.  
 In addition to reducing the prevalence of HPV infection, the HPV vaccine series 
provides partial protection against other cancer-causing HPV serotypes not included in 
the vaccine (Ferris et al., 2014; Petrosky et al., 2015). This information is valuable 
because without directly targeting serotypes of HPV not included in the vaccine, 
antibodies produced against these strains will be able to offer some protection against 
these other strains. Another area of interest in the effectiveness of the HPV vaccines is 
the duration of protection, that is, the amount of time (in years) that one is protected 
against HPV after receipt of the vaccine. From a clinical perspective, the duration of 
protection is critical to preventing HPV infection. For 2vPHV and 4vHPV, after receipt 
of all three doses, the duration of protection is currently estimated to be 8 and 9 years, 
respectively (Naud et al., 2014). However, because the nine-valent HPV vaccine is 
relatively new, its duration of protection is not known. The duration of protection of the 
vaccine is important not only to clinicians but also to public health officials because the 
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longer the duration of protection, the greater the chances of preventing cervical and other 
cancers, such as vaginal, vulvar, and oropharyngeal cancers, that are HPV-related 
(Harper & DeMars, 2017; Naud et al., 2014).  
 One of the objectives of Healthy People 2020 (2018) is to reduce the prevalence 
of STIs by promoting healthy sexual behaviors. This goal can be accomplished by 
increasing access to services that will help to control STIs and prevent adverse health 
outcomes associated with these infections (Healthy People 2020, 2018). For HPV, the 
goal is to reduce the proportion of female adolescents who are infected with HPV 
(Healthy People 2020, 2018). In the United States alone, 14 million new cases of HPV 
are diagnosed each year, with approximately 50% of new cases occurring in persons 15 
to 24 years of age (CDC, 2017). Reducing HPV infections is critical not only because 
HPV infection is the most common STI but also because HPV is linked to a high 
percentage of cervical, vaginal, vulvar, and oropharyngeal cancers in women (CDC, 
2017).  
Individual and Contextual Factors That Influence HPV Vaccination 
 Despite the effectiveness of the HPV vaccines, issues relevant to noncompletion 
of the series continue. Highlighted in this section are individual and contextual factors 
that influence completion of the vaccine series. These factors include age and gender, 
race and ethnicity, nativity, socioeconomic status, perceptions about the vaccine, health 




Age and Gender 
 Adolescents should receive the HPV vaccine series before they start engaging in 
sexual activity to prevent the spread of HPV and the development of genital warts and 
reduce the likelihood of developing HPV-related cancers (CDC, 2017). Currently, the 
HPV vaccines are recommended for adolescent girls 11 and 12 years of age, even though 
it can be administered to girls as young as 9 years of age (CDC, 2017). For girls and 
young female adults 13 to 26 years of age who were not vaccinated or have not 
completed the vaccine series within the specified time frame, the CDC (2017) 
recommended catch-up vaccines. However, because the vaccine targets young adolescent 
girls, the decision to vaccinate is at the discretion of the parents or, in most cases, the 
mothers (Fernandez et al., 2010).  
 Some researchers have found that when compared to girls 13 to 17 years of age, 
girls 11 and 12 years of age are less likely to complete the HPV vaccine series (Niccolai 
et al., 2011; Reiter, Katz, & Paskett, 2013; Schluterman, Terplan, Lydecker, & Tracy, 
2011). Other researchers have not found any association between age and completion of 
the HPV vaccine series (Dorell et al., 2011; Verdenius et al., 2013; Widdice et al., 2011). 
After controlling for race, insurance, and region of residence, only Cook et al. (2010) 
found that older girls 17 years of age were less likely than girls 11 years of age to 
complete the HPV vaccine series. In another study, age was not consistently found to be a 
factor in completing the HPV vaccine series, but in general, younger girls 9 to 12 years of 
age were more likely than adolescents 13 to 17 years of age to comply with a multidose 
vaccine (Gallagher et al., 2016). What remains unclear is whether these inconsistent 
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findings are associated with the health-seeking behavior of adolescents or whether other 
factors are contributing to these differences (Gallagher et al., 2016). 
 Before 2011, boys were not included in the recommendation to receive the HPV 
vaccine; so most of what is known about the factors influencing completion of the HPV 
vaccine series has been gathered from studies on preadolescent and adolescent girls. 
Since the ACIP expanded its recommendation in 2011 to vaccinate boys routinely against 
HPV (Dunne et al., 2011), researchers have consistently demonstrated that boys have 
been less likely to initiate and complete the HPV vaccine series, irrespective of age, 
insurance status, socioeconomic status, health care usage, and health care center 
characteristics (Henry, Swiecki-Sikora, Stroup, Warner, & Kepka, 2018; Kepka, Ding, 
Hawkins, Warner, & Boucher, 2016; Moss et al., 2013). Using a national representative 
sample of male and female adolescents from the 2014 NIS-Teen, Reagan-Steiner et al. 
(2014), showed that of the male adolescents (41.7%) who initiated the vaccine series, 
only 21.6% completed it. Comparatively, 60% of the female initiated the vaccine series, 
but only 39.7% completed it (Reagan-Steiner et al., 2014). This trend has appeared to be 
specific to the HPV vaccine only because the vaccination rate for other adolescent 
vaccines has tended to be much higher (Brown et al., 2017; Reagan-Steiner et al., 2014). 
Even though the vaccine completion rate has been lower among male adolescents, 
completion rates for male and female adolescents remain well below the national 
standard of 80%. Hence, although it was not within the scope of this study, increasing the 
completion rate of the HPV vaccine series among male adolescents is as much a public 
health priority as it is for female adolescents. 
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Race and Ethnicity 
  Race and ethnicity are significant predictors of completion of the HPV vaccine 
series among adolescents (Niccolai et al., 2011). Compared to non-Hispanic Whites, 
Hispanic, African American, and American Indians adolescent girls have been less likely 
to complete the vaccine series (Elam-Evans et al., 2013; McKeever et al., 2015; Wilson, 
Brown, Carmody, & Fogarty, 2015). Using a nationally representative sample from the 
NIS-Teen, Elam-Evans et al. (2013) showed that HPV vaccine series completion rates for 
Hispanic and African American adolescents were consistently low during the 2010-2013 
cycle. For female adolescents who initiated the vaccine series in 2013, Hispanics and 
African Americans were less likely than White girls of similar age to complete the series 
(Elam-Evans et al., 2013).  
Moreover, these rates have tended to vary from state to state. States with a high 
percentage of adolescent girls from racial and ethnic minorities have tended to have 
lower completion rates (McKeever et al. 2015). For example, Mississippi has been found 
to have the lowest completion rate (19%) when compared to a 57.7% completion rate for 
Rhode Island (Dunne et al., 2014; Elam-Evans et al., 2013). Together, these findings 
suggest that there is either limited access to preventive services or underutilization of 
these services, even if they are accessible.  
Country of Birth 
 According to the U.S. Census Bureau (2013), 4.1% of individuals 10 to 14 years 
of age and 7% of individuals 15 to 19 years of age living in the United States were born 
in other countries. Vaccination practices, access, availability, and schedules in other 
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countries might be different from those in the United States; therefore, vaccine coverage 
among foreign-born persons might be below U.S. national standards (Healy et al., 2018). 
Based on the literature, the country of birth can negatively affect vaccination coverage 
among young children (Varan et al., 2017) and adults (De & Budhwani, 2017; Lu, 
Rodriguez-Lainz, O’Halloran, Greby, & Williams, 2014; Pérez, Agénor, Gamarel, & 
Operario, 2018). For example, compared to U.S.-born infants less than 12 months of age, 
foreign-born infants have lower odds of being up to date on the routinely recommended 
vaccines for this age group (Varan et al., 2017). Likewise, compared to U.S.-born 
children 19 to 35 months of age, foreign-born children of similar ages are less likely to 
complete the combined vaccine series recommended for this group (Varan et al., 2017). 
The same trend also has been observed for adults, whereby foreign-born adults, compared 
to adults born in the United States, 18 to 32 years of age are less likely to initiate and 
complete the HPV vaccine series (De & Budhwani, 2017; Pérez et al., 2018). 
 Until recently, not much was known about the relationship between country of 
birth and vaccine coverage among adolescents. Unlike young children and adults, the 
results of a study by Healy et al. (2018) did not find any association between country of 
birth and coverage rate for the vaccines recommended for this group. Using data from the 
2012-2014 NIS-Teen, Healey et al. found that coverage rates for the measles, mumps, 
and rubella vaccine (MMR); acellular pertussis vaccine; and meningococcal conjugate 
vaccine were comparable for foreign-born and American-born adolescents 13 to 17 years 
of age. Although foreign-born adolescents had a slightly lower coverage rate for hepatitis 
B vaccine, the coverage rate for hepatitis B was high for both groups (Healy et al., 2018). 
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However, for HPV and varicella, the vaccination coverage rate was low for both groups 
(Healy et al., 2018).  
Among foreign-born girls, Healy et al. (2018) found that the unadjusted coverage 
rate for all doses of the HPV vaccine series was less than 38%; however, after adjusting 
for access to health care, socioeconomic factors, and demographic factors, such disparity 
no longer existed. This finding suggests that even though vaccine coverage rates are 
comparable for American-born and foreign-born adolescents, vaccination disparities still 
exist among this cohort. As highlighted in the Healy et al. study, socioeconomic and 
demographic disparities, as well as disparities in health care access, affect vaccine 
uptake, and as seen in this study, they do account for some of the differences seen in 
vaccine coverage among adolescents.  
Perceptions of the HPV Vaccine 
Maternal-Related Factors 
  Mothers’ perceptions of the HPV vaccine are very influential to its uptake 
(Morales-Campos & Parra-Medina, 2017). For some mothers, it has been easier for them 
to justify accepting the vaccine because it prevents cancer (Morales-Campos & Parra-
Medina, 2017; Roncancio et al., 2016, 2017). Some mothers have tended to believe that 
the vaccine is not necessary and that their daughters are too young to get the vaccine 
(Bastani et al., 2011; Laz et al., 2012). Other mothers have perceived that using the 
vaccine would promote sexual activity at a young age or promote high-risk sexual 
practices (Hendry, Lewis, Clements, Damery, & Wilkinson, 2013). However, based on 
the results of several studies, HPV vaccination is not associated with riskier sexual 
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behavior (Bednarczyk, Davis, Ault, Orenstein, & Omer, 2012; Liddon, Leichliter, & 
Markowitz, 2012; Mayhew et al., 2014). 
 The HPV vaccines are relatively new. Since their introduction, mothers have 
continuously voiced their concern about the safety of the vaccines (Berenson, 2015). 
These concerns have revolved around the side effects of the vaccines and any possible 
adverse effects that could affect the overall health and fertility of girls (Berenson, 2015; 
Schuler, Hanley, & Coyne-Beasley, 2014). Despite concerns about the safety of the 
vaccines, the vaccination of adolescent Hispanic girls is likely if the mothers believe that 
the vaccine prevents HPV infection and cervical cancer (Gold, Naleway, & Riedlinger, 
2013; Roncancio et al., 2016). Based on perceived barriers and facilitators to getting the 
HPV vaccines, Hispanic mothers may or may not vaccinate their daughters against HPV 
(Roncancio et al., 2016). For example, availability of transportation, the ease of making 
appointments, and the ability to discuss the matter with health care providers can impact 
the chances of completing the vaccine series (Roncancio et al., 2016, 2017). 
   Maternal acceptability of the vaccine is one of the strongest predictors of 
adolescents not only accepting the vaccine but also actually getting the vaccine 
(Roncancio et al., 2016, 2017). Acceptability of the HPV vaccines is associated with 
maternal knowledge and awareness of HPV, HPV-related cancers, and the HPV vaccines 
(Morales-Campos & Parra-Medina, 2017). Several researchers have cited maternal lack 
of knowledge about HPV, the vaccine, and HPV-related outcomes as a barrier to 
vaccination (Dorell et al., 2011; Laz et al., 2012; Stokely et al., 2014). Likewise, although 
receipt of a recommendation from health care providers regarding HPV vaccination is 
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influential, some mothers view the lack of such recommendations as a sign that the 
vaccine must not be important (Laz et al., 2012; Stokely et al., 2014). Hence, without 
additional information about the vaccines and a recommendation from health care 
providers, adolescents are less likely to complete the vaccine series (Laz et al., 2012; 
Stokely et al., 2014).  
 Risk of HPV infection also has been cited as a barrier to vaccine uptake. Mothers 
who perceive that their children are not at risk of HPV infection or HPV-related cancers 
are less likely to have them vaccinated against the disease (Bastani et al., 2011; Laz et al., 
2012). Conversely, Markovitz, Song, Paustian, and Reda (2014) found that mothers’ use 
of preventive services like the Pap test is more predictive of their daughters receiving the 
HPV vaccines. This finding implies that mothers who are aware of HPV and HPV-related 
cancers and who themselves have taken steps to prevent cervical cancer can positively 
affect the HPV vaccination status of their daughters.  
Adolescent Perceptions About the Vaccine 
   Most adolescents have a basic knowledge or understanding of HPV infection and 
the HPV vaccines (Valentino & Poronsky, 2016). However, depending on where they get 
their information, they might be misinformed about HPV infection and the vaccines 
(Berenson, 2015). One study in Texas by Morales-Campos et al. (2013) found that among 
girls 14 to 17 years of age, many did not know about cervical cancer, what caused it, how 
it could be prevented, or who was at risk of developing it. For adolescents who are 
misinformed, what they know about HPV and the vaccines can negatively affect their 
overall attitude toward them (Forster, Marlow, Wardle, Stephenson, & Waller, 2010; 
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Rambout, Tashkandi, Hopkins, & Tricco, 2014). Some adolescents believe that the 
vaccines are neither necessary nor effective (Forster et al., 2010; Rambout et al., 2014). 
Still, others believe that because they are not sexually active, are married, or are in 
monogamous relationships, the vaccine is not needed (Liddon et al., 2012: Zimet, Weiss, 
Rosenthal, Good, & Vichnin, 2010).  
When adolescent girls value the opinions of their mothers, they are more likely to 
mirror the attitudes and opinions of their mothers (Mullins et al., 2013). In such cases, if 
the mothers do not agree with the HPV vaccine, the daughters also are less likely to 
comply with the three-dose vaccine regiment (Mullins et al., 2013). Adolescents are, 
however, more likely to complete the vaccine series if they perceive that they are at risk 
of HPV infection and cancer and are susceptible to STIs (Kessels et al., 2012). They are 
also more likely to complete the vaccine series if they perceive HPV as severe and 
believe that the vaccine is protective against HPV or can prevent cancer (Morales-
Campos et al., 2013). 
Provider Recommendation 
  Of the factors most often associated with the uptake of the HPV vaccine series, 
receipt of a recommendation from health care providers is the strongest predictor of being 
vaccinated against HPV (Brewer et al., 2011; Gilkey et al., 2015, 2016; Holman et al., 
2014; Lau, Lin, & Flores, 2012; Reiter, McRee et al., 2013). Receipt of a 
recommendation from health care providers to vaccinate against HPV is so instrumental 
that 70% of the recipients of such a recommendation have initiated the vaccine series 
(Dorell et al., 2010). Using a national online survey, Gilkey et al. (2016) found that 75% 
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of the study participants who received a recommendation from their health care providers 
initiated the vaccine series and about 43% of them completed the vaccine series.  
 Despite the impact of health care providers’ recommendation regarding uptake of 
the HPV vaccine, not all adolescent girls receive a recommendation from their health care 
providers (Gilkey et al., 2015, 2016). Girls from racial and ethnic minorities, particularly 
Hispanic and African American girls, are less likely to receive a recommendation to get 
the HPV vaccine from their health care providers (Morales-Campos et al., 2013). Girls 
living below the federal poverty level are also less likely to receive such a 
recommendation (Niccolai et al., 2011). If they have received a recommendation from 
their health care providers, analysis of data from the NIS-Teen 2009 survey showed that 
Hispanics and African Americans were as likely as their White age mates to get the 
vaccine (Ylitalo, Lee, & Mehta, 2013).  
 Among African American and Hispanic adolescents, the lack of a 
recommendation from health care providers to get the HPV vaccine might be associated 
with not having regular medical homes, being uninsured, and using preventive care 
services irregularly, even if they are accessible (Holman et al., 2014). The lack of a 
recommendation by health care providers among ethnic minorities might be exacerbated 
by factors inherent to their status as immigrants (if applicable); among these factors are 
low health literacy, language barriers, low levels of acculturation, and so on (Jeudin et al., 
2014). Gerend et al. (2013) found that the odds of receiving a recommendation to get the 
HPV vaccine series were higher among individuals who were more acculturated than 
among individuals who were less acculturated.  
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 Although the emphasis of health care providers’ recommendation is reflected 
more in the percentage of persons who start the HPV vaccine series, such a 
recommendation is equally important to complete the HPV vaccine series (Kepka et al., 
2015). Health care providers also should stress the importance of completing the vaccine 
series to be protected fully against HPV (Berenson, 2015). The providers should inform 
parents and adolescents that they have to return for the second and third doses (Berenson, 
2015). This oversight was made evident by a study that evaluated the HPV knowledge of 
Hispanics in Utah (Kepka, Ulrich, & Coronado, 2012). The results of this study revealed 
that among the survey participants, most parents were not aware that the HPV vaccine is 
a multidose vaccine (Kepka, Ulrich, & Coronado, 2012). By highlighting the importance 
of initiating as well as completing the vaccine series, health care providers can drastically 
boost the level of HPV vaccine completion among adolescents, especially among 
adolescent girls from racial and ethnic minority groups.  
Financial Barriers 
Cost of the Vaccine 
  The HPV vaccine is one of the most expensive vaccines to date. In U.S. dollars, 
the cost per dose, if using the 4vHPV, ranges from $121 to $160 (CDC, 2015b). If the 
9vHPV is received, the cost ranges from $168 to $204 per dose (CDC, 2018). In total, 
completing either the 4vHPV or the 9vHPV series can cost from $363 to $480 or $504 to 
$612, respectively (CDC, 2015b, 2018). The difference in price is based on whether the 
vaccine is covered or not covered by public or private insurance. The lower prices are for 
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Medicaid or Vaccination for Children (VFC) recipients, and the higher prices are for 
those with private insurance or who are paying out of pocket (CDC, 2018).  
 For parents, the cost of the vaccine can be burdensome. Not every adolescent is 
eligible for Medicaid, and not everyone can afford private insurance or pay for the 
vaccine out of pocket (Bruno, Wilson, Gany, & Aragones, 2014; Warner et al., 2015). 
Likewise, not everyone qualifies for the VFC program, which provides the vaccine at no 
cost to eligible recipients (CDC, 2016d). Furthermore, even if the children qualify for 
VFC, some parents might not know about this program (Reiter, Katz, & Paskett, 2013). 
Persons without insurance coverage might struggle to pay the high cost of the vaccine or 
might even choose not to get it because they might view it as a nonurgent medical matter 
(Nordin, Solberg, & Parker, 2010).  
Health Care Providers’ Administrative Fees 
 From the perspective of health care providers, it is difficult for doctors to store 
and administer the vaccine to their patients (Quinn, Murphy, Malo, Christie, & 
Vadaparampil, 2012). In their private practices, doctors pay for and stock the vaccine so 
that it is readily available to administer to patients. In addition to paying for the vaccines 
themselves, doctors absorb the cost of storing and administering the vaccine. Although 
they keep the vaccine in stock as a service to their patients, they stand to lose or gain very 
little from doing so because they are reimbursed poorly for this service (Gable, Eder, 
Noonan, & Feemser, 2016). Without incentives, health care providers might be less 
inclined to offer such services or recommend the vaccine to persons who are either 
underinsured or uninsured (Pourat & Jones, 2012; Ylitalo et al., 2013). Because girls 
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from racial and ethnic minority groups are more likely to be underinsured or uninsured, 
they are less likely to receive a recommendation for the HPV vaccination from their 
health care providers. 
Socioeconomic Status 
 Low socioeconomic status, that is, lower disposable income and lower education, 
highly correlates with the incidence of cervical cancer in the United States (González et 
al., 2015). However, relative to the HPV vaccine, very few studies in the United States 
have captured the ways that socioeconomic factors affect the uptake of the vaccine series 
among adolescent girls. Results of these few studies have either been insignificant or 
conflicting, indicating that HPV vaccination uptake was less likely among individuals 
living below the poverty level (Fisher, Trotter, Audrey, MacDonald-Wallis, & Hickman, 
2013; Roberts et al., 2010) or was not associated with low income (Pruitt & Schootman, 
2010).  
  Family income. Polonijo and Carpiano (2013) analyzed data from the 2008-2010 
NIS-Teen to assess social inequalities associated with vaccinating adolescents against 
HPV. Based on their analysis, yearly estimates of household income from 2008 to 2010 
were inconsistently associated with completion of the vaccine series. Likewise, the odds 
of completing the vaccine series were significantly lower (23%-25%) for girls from low- 
and middle-income households than for girls from higher-income households (Polonijo & 
Carpiano, 2013). However, multivariate analyses from other studies showed that parental 
income (Gold et al., 2013; Laz et al., 2010); neighborhood income; and household 




 Results of a study conducted in Denmark by Slåttelid Schreiber, Juul, 
Dehlendorff, and Kjaer (2015) showed that despite having free access to the HPV 
vaccine, adolescent girls from ethnic minority groups were less likely to initiate and 
complete the vaccine series. Compared to Danish adolescent girls from households with 
parents having more disposable income, adolescent girls whose parents had less 
disposable income were less likely to initiate and complete the vaccine series (Slåttelid 
Schreiber et al., 2015). Likewise, compared to Danish girls whose mothers were married 
and employed, girls whose mothers were unmarried and unemployed tended to have 
lower odds of initiating and completing the vaccine series (Slåttelid Schreiber et al., 
2015).  
   Another study conducted in Norway (B. T. Hansen, Campbell, Burger, & Nygard, 
2015) did not find an association between socioeconomic factors and completion of the 
vaccine series. In this study, B. T. Hansen et al. (2015) noted that initiation of the vaccine 
series correlated with parental ages and incomes, receipt of the MMR vaccine, and 
maternal occupations. However, only receipt of the MMR vaccine correlated with 
completing the HPV vaccine series; socioeconomic factors did not have any effect on 
completion rate (B. T. Hansen et al., 2015). If the girls did not receive the MMR vaccine, 
their chances of completing the HPV vaccine series was considerably lower than if they 
had been vaccinated (B. T. Hansen et al., 2015).   
Maternal education. Polonijo and Carpiano (2013) identified an association 
between maternal education and completion of the vaccine series varies. They concluded 
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that as the level of maternal education decreased, the odds of completing the HPV 
vaccine series were 11% to 28% lower for uneducated versus college-educated mothers. 
Multivariate analyses from another study showed that the level of parental education was 
not associated with completion of the HPV vaccine series (Fisher et al., 2013).  
The study conducted by Slåttelid Schreiber et al. (2015) showed that despite 
having free access to the HPV vaccine, adolescent girls from ethnic minorities were less 
likely to initiate and complete the vaccine series. Compared to Danish adolescent girls 
from households with parents having higher levels of education, adolescent girls whose 
parents were less educated were less likely to initiate and complete the vaccine series 
(Slåttelid Schreiber et al., 2015). However, B. T. Hansen et al. (2015) did not find any 
association between education and completion of the HPV vaccine series. B. T. Hansen et 
al. concluded that even though initiation of the vaccine series correlated with parents’ 
educational attainment, receipt of the MMR vaccine, and maternal occupation, only 
receipt of the MMR vaccine correlated with completing the HPV vaccine series. Thus, 
they argued that socioeconomic factors did not have any effect on completion of the 
vaccine series. It was more likely that if the girls did not receive the MMR vaccine, they 
were less likely to complete the HPV vaccine series (B. T. Hansen et al., 2015).   
Hispanics and the Risk of HPV 
Hispanic Health 
 Hispanics are the fastest growing and the largest ethnic group in the United States. 
Currently, the Hispanic population accounts for 17.6% (56.5 million) of the U.S. 
population and comprises Mexicans (66%), individuals from South and Central America 
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(13%), Puerto Ricans (9.5%), Cubans (4%), and other Hispanics (7.5%; Pew Research 
Center, 2017; U.S. Census Bureau, 2013). Hispanics under the age of 18 years account 
for approximately 17% of the U.S. population of children, and this percentage is expected 
to increase to 28.6% by 2060 (Colby & Ortman, 2014).  
 Hispanics are an exceptional class of immigrants. Although they are 
disadvantaged socioeconomically, their overall health is better than that of African 
Americans and non-Hispanic Whites (Camacho-Rivera, Kawachi, Bennett, & 
Subramanian, 2015). This health advantage has been associated with some sociocultural 
factors that are protective against unhealthy behaviors (Lam, Goldenson, Burner, & 
Unger, 2016). These factors include family, religion, and cultural or traditional beliefs 
and practices that promote certain behaviors that are not destructive to one’s overall well-
being (Johnson-Motoyama, 2014; Lam et al., 2016). However, the longer that Hispanic 
individuals reside in the United States, the more they are exposed to behaviors that 
ultimately cause them to lose their health advantage (Camacho-Rivera et al., 2015; Ro, 
2014).  
 Deterioration in the health of Hispanics has been partially attributed to social and 
structural factors that shape the conditions in which they live (Velasco-Mondragon et al., 
2016). Among these factors are lower levels of education, lack of access to health care 
services, lower socioeconomic status, underinsured or uninsured status, and low-paying 
jobs (Velasco-Mondragon et al., 2016). These challenges are further compounded by 
federal and state policies and practices that restrict their access to health services and 
social programs (Johnson-Motoyama, 2014). It has been estimated that more than 80% of 
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Hispanic children (i.e., < 18 years of age) born in the United States are the children of 
unauthorized immigrant parents (Passel & Cohn, 2011). As U.S. citizens, these children 
would naturally qualify for most programs, but because of laws and policies that affect 
their parents negatively, they cannot participate in such programs (Johnson-Motoyama, 
2014; Seiber, 2013). This fact is important to note because it offers some explanation for 
the high percentage of Hispanic children and adolescents who are underinsured or 
uninsured and why they access preventive care services sporadically, if at all (Schmeer, 
2012).  
HPV Among Hispanics 
  In the United States, Hispanic women have the highest incidence of cervical 
cancer (ACS, 2017; Kepka et al., 2015). They are 2 to 3 times more likely to develop 
cervical cancer because of persistent infection with genital HPV and are less likely to 
have had a Pap test (ACS, 2017; Lechuga et al., 2016). Compared to non-Hispanic White 
women, the incidence of cervical cancer among Hispanic women is 74% higher, and the 
mortality rate among this group of women is 48% higher (ACS, 2017). Each year, 
approximately 2,000 Hispanic women are diagnosed with cervical cancer, and 
approximately 600 of them die from the disease (ACS, 2017). Given the incidence of 
cervical cancer among Hispanic women, HPV vaccination might be of great importance 
to this group of women. Researchers have shown that even though Hispanic adolescent 
girls are more likely to initiate the HPV vaccine series, they are less likely than non-
Hispanic White adolescent girls to complete the three-dose series (Jemal et al., 2013; 
Niccolai et al., 2011; Polonijo & Carpiano, 2013). Over time, if this pattern of vaccine 
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coverage persists among Hispanic girls, the gap in HPV-related disparities for this group 
of women is likely to widen (Roncancio et al., 2017).  
Acculturation, Health Literacy, Social Influence, and HPV Vaccination  
 Relative to Hispanics and the reduction of their risk of HPV infection, 
acculturation might not only be a barrier but also a facilitator of their being vaccinated 
(Gerend et al., 2013; Held & Cuellar, 2016; Kepka et al., 2015). Acculturation refers to a 
sociocultural process through which individuals from a cultural group adapt to the culture 
of the host country as a result of exposure to its values, beliefs, attitudes, behaviors, and 
customs (Lopez-Class, Castro, & Ramirez, 2011; Ward & Geeraert, 2016). Individuals 
vary in their level of acculturation, and based on their level of acculturation, they might 
or might not be at a disadvantage for poor health outcome (Lopez-Class et al., 2011; 
Ward & Geeraert, 2016). For example, individuals who are more acculturated are more 
likely than individuals who are less acculturated to receive a recommendation for HPV 
vaccination from their physicians (Gerend et al., 2013). Conversely, a high level of 
acculturation is associated with adopting behaviors such as engaging in risky sexual 
practices that increase the risk of HPV, as suggested by Kepka, Coronado, Rodriguez, 
and Thompson (2010). Analysis of data from the 2003-2004 National Health and 
Nutrition Examination Survey indicated that Mexican American women who were more 
acculturated than women who were less acculturated were more likely to be infected with 
high-risk HPV serotypes (Kepka et al., 2010).  
   Although researchers have contended that acculturation has a positive effect on 
disease prevention (Breen, Rao, & Meissner, 2010; Lebrun, 2012), how it correlates with 
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completing the HPV vaccine series remains unclear. Some researchers have reported not 
finding an association between acculturation and initiation of or intention to initiate the 
HPV vaccine series (Guerry et al., 2011; Luque et al., 2010). In other studies, 
acculturation has been reported as a barrier to the uptake of the HPV vaccine (Walter et 
al., 2017) and that acculturation has contributed to the racial and ethnic disparities 
associated with the uptake of the HPV vaccine (Wisk et al., 2014). However, Gerend et 
al. (2013) found that acculturation was associated with the uptake of the HPV vaccine, 
meaning that more acculturated mothers were more likely than mothers who were less 
acculturated to have their children vaccinated against HPV.  
 Individuals who are less acculturated tend to have limited health literacy, which 
impedes their ability to make health-related decisions and to follow certain health-related 
directives (Ciampa et al., 2012). As such, Hispanics or Spanish speakers are at a higher 
risk of experiencing problems related to health literacy (R. Singh, Coyne, & Wallace, 
2015). Besides having variations in HPV-related knowledge, having limited health 
literacy also might prevent Hispanics from accessing better HPV-related information and 
then processing such information to help them to make more informed decisions about 
receiving the vaccine (Baldwin, Bruce, & Tiro, 2013). HPV literacy among Hispanic 
mothers is associated with a higher chance of their daughters being vaccinated against 
HPV, thus reducing the children’s risk of infection (Beltran, Simms, Lee, & Kwon, 2015; 
Wisk et al., 2014). Hispanic mothers with low literacy have lower odds of vaccinating 
their daughters against HPV, thus increasing their daughters’ risk of HPV infection 
(Beltran et al., 2015; Wisk et al., 2014). The same is true of mothers who are unaware of 
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or have limited knowledge of HPV, the vaccine, and HPV-related diseases (Beltran et al., 
2015; Wisk et al., 2014).  
 The literature has shown that immigration disrupts the social networks of 
Hispanic immigrants. Compared to U.S.-born Hispanics, foreign-born Hispanics tend to 
have lower social support, meaning that they will have fewer sources at their disposal to 
assist them in making health-related decisions (Allen et al., 2014). For Hispanics, the 
family is highly valued and is integral to the decision-making process. The nursing 
theory-health promotion model posits that people are more likely to obtain health 
information from peers, friends, and family members, and are subsequently more likely 
to engage in health behaviors that positively affect their health when people in the social 
circle model the behaviors and show their support to enable the behaviors (Nursing 
Theory, 2016). Therefore, for immigrants who are socially connected, having other 
people who model or support certain health-related behaviors (e.g., vaccinating against 
HPV) reflects the likelihood of engaging in such behaviors. If they know someone who 
has completed the vaccine series or has cervical cancer, Hispanic mothers are more likely 
to vaccinate their daughters against HPV (Morales-Campos et al., 2013; Stephens, Tamir, 
& Thomas, 2016). Likewise, adolescent girls are more likely to get the vaccine if they 
know that their friend(s) have gotten the vaccine. Likewise, the negative experiences of 
others, their negative attitudes toward health care providers, and the type of information 
relayed about HPV and the HPV vaccine can adversely affect the decision to be 
vaccinated (Stockwell, Irigoyen, Martinez, & Findley, 2011).  
57 
 
 Because newly immigrated Hispanic mothers might not have the resources (e.g., 
health insurance or access to health information) to maintain the health of their families, 
it is important for them to be socially connected (W. Kim, Kreps, & Shin, 2015). Being 
acculturated and socially connected are important because interacting with others will 
serve as a source of information (e.g., affordable services, the location of clinics, etc.). In 
addition, by interacting with other mothers, they will learn about the health-related norms 
of the host country (W. Kim et al., 2015). Mothers who associate with others who have 
accepted the HPV vaccine are more likely to ensure that their children receive the vaccine 
as recommended. For mothers who are unacculturated or who are not health literate, 
people in their social networks can be a source of information, and they can help the 
mothers to find the necessary information and resources (Y. C. Kim, Lim, & Parks, 
2015).  
Access to Health Care and HPV Vaccination 
    Receiving a health care provider recommendation for HPV vaccination and 
having regular preventive care visits are critical to the uptake of the HPV vaccines. 
Adolescent girls from racial and ethnic minority groups and girls from families with 
lower socioeconomic status are more susceptible to having limited access to preventive 
care services and receiving poorer quality of care (Gelman et al., 2013; Polonijo & 
Carpiano, 2013). Hispanics are distinctly at a disadvantage in terms of receiving quality 
and appropriate care to meet their needs. Whether seeking to address medical issues or 
use preventive services, Hispanics in the United States have limited access to health 
services and are less likely to have primary medical homes. They also are less likely than 
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other racial and ethnic groups to use preventive care services (Gelman et al., 2013; 
Velasco-Mondragon et al., 2016). Because health care providers are needed to administer 
the vaccine, adolescents from racial/ethnic minority groups who have limited or no 
access to preventive care services will continue to be underimmunized (Gelman et al., 
2013).  
 Even if their primary health care providers are accessible, many U.S. adolescents 
do not see them for the recommended annual well-care visit (Bruno et al., 2014). Based 
on a survey of physicians servicing racial/ethnic minority communities, about 70% of 
these doctors reported that a limiting factor for receiving a recommendation for the HPV 
vaccine was the lack of preventive care visits by eligible adolescents (Bruno et al., 2014). 
Even with insurance coverage, Tsai, Zhou, Wortley, Shefer, and Stokley (2014) 
commented that among adolescents who are privately insured, approximately 43% of 
them had made at least one preventive care visit at the time of the study. Relative to the 
HPV vaccine, this fact is concerning because preventive care visits are the ideal situations 
for health care providers to recommend and administer the vaccine (Berenson, 2015).  
 Dorell et al. (2011) reported that after controlling for sources of information and 
health care utilization, adolescent girls and young adult females were more likely to 
receive the HPV vaccine series if they had made recent health care visits and had 
discussed getting vaccinated with their health care providers. Preventive care usage also 
varies by U.S. state (Moss, Reiter, & Brewer, 2015). For girls living in states with high 
percentages of preventive care service usage, Moss et al. (2015) found that the likelihood 
of completing the HPV vaccine series was higher among these girls than among girls 
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living in states with lower percentages of preventive care usage. These findings suggest 
that interactions with health care providers and residence in areas where the use of 
preventive care services is high influence the likelihood of being vaccinated. 
 Having primary medical homes is crucial. Test, Caskey, and Rankin (2013) 
evaluated the relationship between receiving the HPV vaccine series and having 
permanent medical homes. They concluded that girls with permanent medical homes 
were more likely than girls without permanent medical homes to get the vaccine. This 
finding suggests that having permanent medical homes is influential in the uptake of the 
vaccine. In another study (Perreira et al., 2012), Hispanics were found to be less likely to 
have permanent medical homes and turned, instead, to hospitals, community health 
centers, public clinics, or school-based health centers to meet their health care needs. By 
using these different facilities, some parents might not recognize the need to establish 
permanent medical homes (Banspach et al., 2016; Nordin et al., 2010).  
From a public health perspective, these facilities are attractive because they can 
serve as points of contact to help in delivering the HPV vaccine to ensure that girls can 
either initiate or complete the vaccine series (Guleria, Jones, Zimmerman, Stempinski, & 
Patel, 2016). Besides being points of care for delivering the vaccine, these sites have the 
potential to help to address such issues as differences in language and literacy levels that 
impact the patient-provider relationship (Javier, Festa, Florendo, & Mendoza, 2015). 
They also might help to address barriers specific to the health care system, such as 
geographic availability and staff competency (Javier et al., 2015). Using different facility 
types to obtain health care services does not eliminate the need to establish primary 
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medical homes, but they do have the potential to help to reduce disparities in access to 
health care services. The role that they play in delivering the HPV vaccine might also 
offer further insight into differences seen in the uptake of the HPV vaccine among 
adolescents.  
Insurance Coverage and HPV Vaccination 
 The most cited reasons for not accessing health care services are either the lack of 
health insurance or inadequate insurance (G. K. Singh et al., 2013). The HPV vaccine 
series is costly (Lu et al., 2018), so without coverage by private insurance or Medicaid, it 
might be a struggle for some parents to pay for it out of pocket. Children of immigrant 
parents have lower health insurance coverage than children of U.S.-citizens (Jarlenski et 
al., 2016). Compared to other racial and ethnic minority groups, Hispanics tend to have 
the highest percentage of uninsured children and adolescents (Berdahl, Friedman, 
McCormick, & Simpson, 2013; G. K. Singh et al., 2013). Likewise, most people living 
below the poverty level are either African American or Hispanic, so from this 
perspective, African Americans also are likely to have a high percentage of uninsured 
children (Jeudin et al., 2014).  
  Being underinsured or uninsured does affect the likelihood of being vaccinated 
against HPV. In general, researchers have determined that private insurance holders have 
higher odds of completing the vaccine series than individuals who are either uninsured or 
are covered by public insurance (Dorrell et al., 2011; Harper et al., 2014; Widdice et al., 
2011). Researchers analyzing data from the NIS-Teen have found that vaccine initiation 
and completion were the lowest among adolescent girls who were not insured (Reiter, 
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Katz, et al., 2013; Reiter et al., 2014). What was striking about this finding is that these 
girls qualified for free vaccines under the VFC Program, but whether they even knew 
about the program or their eligibility was unclear (Reiter et al., 2014).  
Eligibility and free HPV vaccination do not necessarily mean that the rate of 
completing the vaccine series will increase (Harper et al., 2014). In a retrospective cohort 
study, Harper et al. (2014) found that providing the HPV vaccine at no cost did not 
significantly influence completion of the vaccine series; in fact, none of the recipients of 
the free vaccine completed the series. This finding suggests that other factors might have 
been contributing to this outcome. 
   Whether privately or publicly insured, continuity in coverage or maintenance of 
coverage is critical to receipt of the vaccine (Rand & Goldstein, 2018). Based on the 
literature, insurance coverage is normally assessed at a single point in time, usually at the 
time of the medical visit or when the survey is administered. However, in doing so, 
researchers have failed to capture periods when persons were uninsured resulting from 
discontinuity in coverage (Cowburn et al., 2014; DeVoe et al., 2015). For vaccines that 
are administered in a single does, discontinuity or gaps in insurance coverage might not 
be as worrisome, but for multidose vaccines like the HPV vaccine series, this gap can be 
problematic (Cowburn et al., 2014). As recommended, the HPV vaccine is administered 
over 6 months, that is, at baseline (0 months), 2 months, and 6 months. However, not 
everyone adheres to this schedule, so some individuals might need more than 6 months to 
complete the series. During this time, insurance coverage status might change, thus 
affecting the likelihood of completing the vaccine series (Cowburn et al., 2014). When 
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insurance status is measured at a single point in time, it is difficult to assess the ways that 
discontinuity in coverage might influence the uptake of multidose vaccines like the HPV 
vaccine series (Cowburn et al., 2014). 
 Discontinuity in insurance coverage or gaps in insurance coverage might be as 
problematic as being uninsured. Discontinuity in coverage has been associated with 
limited or inconsistent use of preventive services, unmet medical needs, and the inability 
to fill prescriptions (DeVoe et al., 2015; Guevara et al., 2014; Wisk & Witt, 2012). Based 
on the literature, being Hispanic adolescents 10 to 18 years of age from families with 
incomes below the federal poverty level predicts whether or not the children are likely to 
experience gaps in insurance coverage (DeVoe et al., 2015; Fairbrother et al., 2011). 
Similarly, being adolescents in families where only one parent is employed also predicts 
whether the children are continuously insured, or not (DeVoe et al., 2015). For employer-
provided insurance, the parents might not be able to afford family coverage, so the 
children of these parents might not have any coverage for an extended period (DeVoe et 
al., 2011). Similarly, for individuals who rely on employer-provided health insurance, 
changes in parental employment status can lead to changes in coverage or even the loss 
of coverage (Smits-Seemann et al., 2016).  
 Regarding vaccinations, being insured continuously should not matter for children 
less than 18 years of age. This is because children who are uninsured, underinsured, or 
eligible for Medicaid can still get vaccines at no cost through the VFC Program (CDC, 
2016d). However, DeVoe et al. (2015) and Yamauchi, Carlson, Wright, Angier, and 
DeVoe (2013) noted that parental insurance status does affect the insurance status of the 
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children, that is, continued parental coverage increases the likelihood of the children 
maintaining coverage. This finding suggests that disrupting parental insurance coverage, 
whether private or public, is likely to affect the children’s coverage. 
 Cowburn et al. (2014) specifically looked at insurance continuity and HPV 
vaccine uptake in two states and found that for adolescents 13 to 17 years of age, 
insurance continuity did matter. Analysis of data from federally qualified health centers 
in the two states showed that adolescents 13 to 17 years of age were significantly less 
likely to initiate the HPV vaccine series if they were not insured continuously. However, 
in their study, Cowburn et al. stated that insurance coverage did not significantly predict 
the likelihood of completing the vaccine series. One shortcoming of the study was that 
Cowburn et al. were limited to using electronic health records specific to these centers, 
meaning that they could not assess how the data compared to the data of existing vaccine 
registries. 
It also was possible that different categories of insurance coverage affected uptake 
of the HPV vaccine series or that the disruption in insurance coverage or no coverage at 
all was underestimated by Cowburn et al. (2014). Taken together, disparities in vaccine 
relative to insurance status could have been attributed to the underreporting of 
vaccination status, thus limiting the findings of their study. Overall, gaps in insurance 
coverage are not uncommon and should be taken into consideration when assessing 




 Completing the HPV vaccine series is important to all adolescents. However, it is 
more important for Hispanic adolescent girls to complete the series, given that Hispanic 
women have the highest incidence of cervical cancer. Despite the availability and 
effectiveness of the HPV vaccine, completion of the series remains low among 
adolescent Hispanic girls. Although Hispanic adolescent girls are more likely than non-
Hispanic White girls to initiate the vaccine series, they are less likely to complete it for a 
variety of reasons, including having limited access to health care and being underinsured 
or uninsured. Because Hispanic adolescents are less likely to have permanent medical 
homes, they also are less likely to have at least one annual well-care visit, and they are 
more likely to have their health care needs met at other facilities, making it unlikely that 
they will receive the vaccine during these visits. To maximize uptake of the HPV vaccine 
series, it should be offered at all visits, irrespective of where the visits occur.  
Similarly, insurance status also can impact access to the vaccine. To be specific, 
continuity in insurance coverage is crucial to adolescent health. For adolescents, 
obtaining and maintaining health insurance coverage is determined by their parents’ 
insurance status. Parental insurance coverage decreases the likelihood of gaps in 
insurance coverage for the children. Being insured continuously means sustained access 
to preventive services and stability of care (i.e., multiple visits to complete the vaccine 
series).  
  Despite evidence supporting the effectiveness of the HPV vaccine series, the 
limited uptake of the vaccine among the high-risk population remains a concern. To 
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address disparities in HPV vaccine coverage and HPV-related disparities among Hispanic 
women, efforts to increase uptake of the HPV vaccine series among this population are 
needed. Guided by this review of the literature, the current study helped to fill a gap in 
the literature by assessing the ways that the source of health care and continuity in 
insurance coverage influenced completion of the HPV vaccine series among Hispanic 
girls. Analyzing the role of different sources of health care on the uptake of the HPV 
vaccine helped to clarify whether using the facilities in question would facilitate greater 
uptake of the vaccine among Hispanic adolescents. To address issues regarding health 
insurance coverage, it was important to know whether lapses in insurance coverage 
would affect the likelihood of completing the HPV vaccine series. 
 Insurance coverage or gaps in insurance coverage and the source of health care 
accessed had not been assessed quantitatively in relation to completion of the HPV 
vaccine series among Hispanic adolescent girls. Therefore, the purpose of this study was 
to determine if insurance coverage, more specially, gaps in insurance coverage and the 
type of medical facility accessed for health care, correlated with low rates of HPV 
vaccine series completion among Hispanic adolescent girls. In Chapter 3, I present the 








Chapter 3: Research Method 
Introduction 
 Hispanic adolescent girls are less likely to complete the HPV vaccine series 
(Kepka et al., 2015; Roncancio et al., 2017; Walker et al., 2017). Losing insurance 
coverage, even for a short time, can have a negative impact on the likelihood of 
continued care and preventive service usage (DeVoe et al., 2015). Based on the literature 
reviewed, adolescents from racial and ethnic minority groups are more likely to 
experience lapse in insurance coverage for extended periods (DeVoe et al., 2015; Gelman 
et al., 2013). Prior to this study, the extent to which insurance coverage gaps affect 
uptake of the HPV vaccine series had not been explored fully (Cowburn et al., 2013; Lu 
et al., 2018). Using provider-verified HPV vaccine data from a nationally representative 
sample of Hispanic adolescent girls, I assessed the extent to which discontinuity in 
insurance coverage influenced completion of the HPV vaccine series in this study. I also 
assessed the ways that gaps in insurance coverage affected Hispanic girls’ access to their 
primary care provider for HPV vaccination. The dependent variable in the study was 
HPV vaccination status (i.e., being vaccinated or not vaccinated), and the independent 
variables were insurance coverage (i.e., insurance status of the adolescent) and the type of 
medical facility used to access health care. Covariates included maternal age, family 
income, maternal education, and health care provider recommendations.  
 The purpose of this chapter is to present the study design, methodology, and data 
analysis plan that I used to assess the relationship between insurance coverage, type of 
medical facility used to access health care, and uptake of the HPV vaccine series. In this 
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chapter, I also discuss the target population of interest and the sample size. Because I 
analyzed secondary data from the 2016 NIS-Teen were analyzed, I include an 
explanation of the original data collection instrument and protocol. In this chapter, I also 
explain the ethical procedures relevant to collecting and storing the data, 
operationalization of the variables of interest, and relevant threats to the validity of the 
study. 
Research Design and Rationale 
 In this study, I used a quantitative, cross-sectional design to assess the relationship 
between insurance coverage, source of health care, and completion of the HPV vaccine 
series. A cross-sectional research design was appropriate for this study to determine if 
there was a relationship between insurance coverage, type of medical facility used to 
access health care, and completion of the HPV vaccine series because with this design, it 
was possible to assess the nature of the relationship between two or more variables (i.e., 
if changes in one or more of the independent variables was related to changes in the 
dependent variable; Setia, 2016). Cross-sectional studies allow researchers to assess the 
strength and direction of relationships (Setia, 2016; Thiese, 2014). The cross-sectional 
research design allows researchers to measure the exposure and outcome within the 
sample simultaneously (Setia, 2016; Thiese, 2014). Although the cross-sectional research 
design allows researchers to assess the association between exposure and outcome, it 
does not allow researchers to establish any cause and effect between and among variables 
(Setia, 2016; Thiese, 2014). For example, if a relationship between insurance coverage 
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and HPV vaccination status had been found, it would not have been possible to conclude 
that a lack of insurance coverage was the reason for not being vaccinated against HPV.   
Methodology 
 In this section, I explain how the study was conducted and provide information 
about the target population, the sample size, and the sampling technique. In this section, I 
discussed how the variables of interest were operationalized, the instrument used to 
collect the data, and the data analysis plan. In this section, I also discussed threats to 
validity of the study and the ethical considerations that are applicable to the study.  
Target Population 
  The target population comprised of Hispanic adolescent girls 13 to 17 years of 
age. Approximately 17% of the U.S. populations of children who are younger than 18 
years of age are Hispanic (Colby & Ortman, 2014). Of this percentage of Hispanic 
children, national data have suggested that more than 70% of them have been and remain 
underinsured or uninsured (Gelman et al., 2013; Polonijo & Carpiano, 2013), a situation 
that has made them more susceptible to having limited access to preventive care services.  
Sampling and Sampling Procedure 
 In this study, I used secondary data from the 2016 NIS-Teen (CDC, 2016a). As an 
adjunct to the NIS-Child, the NIS-Teen is administered to monitor vaccine coverage 
among adolescents 13 to 17 years of age (CDC, 2016a). The NIS-Child is conducted 
annually and targets households in the United States and select territories with children 
19 to 35 months of age (CDC, 2016a). Initially, the households are screened for the 
presence of children 19 to 35 months of age and are administered the NIS-Child (CDC, 
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2016a). These households are then screened for the presence of adolescents 13 to 17 
years of age (CDC, 2016a). If adolescents are present in these households, the parents or 
guardians who are the most informed about the adolescents’ vaccination histories are 
interviewed (CDC, 2016a). In households with more than one adolescent, one adolescent 
between 13 and 17 years of age is randomly chosen to be the subject of the interview 
(CDC, 2016a). Household interviews for the 2016 NIS-Teen began on January 14, 2016, 
and ended on February 9, 2017, with data being collected from health care providers from 
February 2016 to March 2017 (CDC, 2016a). The 2016 NIS-Teen targeted adolescents 
born between January 1998 and February 2004, and only participants living in the United 
States and select U.S. territories and who were not institutionalized at the time of the 
survey were interviewed (CDC, 2016a).  
 The survey was administered in two phases using random digital dialing (CDC, 
2016a). The first phase, the household telephone survey, was administered to respondents 
whose telephone numbers were selected randomly from a list of landline and cell phone 
numbers (CDC, 2016a). For landline numbers, the telephone survey used quarterly 
samples of telephone numbers (CDC, 2016a). Each quarter, the sample of telephone 
numbers is updated to reflect new telephone numbers and area codes (CDC, 2016a). For 
the cell phone numbers, the respondents were selected randomly from all banks of cell 
phone numbers (CDC, 2016a). Each quarter, landline and cell phone numbers are 
sampled within estimation areas (CDC, 2016a). For the 2016 administration of the 




Based on this design, each cycle of the survey was estimated to have a specific 
degree of precision, meaning that a combination of landline telephone and cell phone 
respondents would yield a target of 6.5% coefficient of variation (CDC, 2016a). To 
achieve this level of precision, statistical modeling was used to predict the number of 
sample telephone numbers (i.e., landline and cell phone numbers) needed to meet this 
target (CDC, 2016a). Preliminary analysis of the unweighted 2016 NIS-Teen data files 
showed that more than 13 million telephone numbers were screened, and from that 
number, 44,771 households with age-eligible adolescents completed the household 
interviews (CDC, 2016a). This number included samples from the landline telephone (n = 
9,502) and cell phone (n = 35,269) interviews (CDC, 2016a). The 2016 NIS-Teen public 
use file that I used in this study comprised data from 43,071 households, excluding 
participants from Guam and the U.S. Virgin Islands (CDC, 2016a).  
 The second phase of the survey involved checking vaccination records with the 
respective providers (CDC, 2016a). During the interviews, the parents of the eligible 
children were asked to provide the names of the health care providers who administered 
the HPV vaccine series to their children (CDC, 2016a). They also were asked for 
permission to contact those providers (CDC, 2016a). Once this permission was received 
from the respondents, the health care providers were invited to complete immunization 
history questionnaires to verify the vaccination information provided by the respondents 
(CDC, 2016a). A preview of the data indicated that 33,389 health care providers 
completed and returned the immunization history questionnaires and that 20,475 of these 
71 
 
questionnaires provided adequate vaccine histories relative to the adolescents of interest 
(CDC, 2016a). 
Sample Size and Power 
 I used G*power 3.1 (Faul, Erdfelder, Lang, & Buchner, 2013) to calculate the 
power needed to detect the likelihood of a statistically significant relationship between 
insurance coverage, the type of medical facility used to access health care, and 
completion of the HPV vaccine series, if such significance was present. For this analysis, 
a compromise power analysis was used; this analysis facilitated calculating the power and 
implied alpha, given the sample size, beta/alpha (β/α) ratio, and effect size. For this 
study, I based all statistical analyses on weighted data. However, for the purpose of this 
power analysis, a subset (n = 1,592) of the data was used for sample size. An odds ratio 
(OR) of 1.68 was used in this power analysis. The odds ratio was estimated from previous 
studies (Hofman et al., 2013; Okuhara, Ishikawa, Okada, Kato, & Kiuchi, 2018; Pot et 
al., 2017) using a small effect size (Cohen’s d) of 0.20, which was equivalent to an  
OR = 1.68 (Chen, Cohen, & Chen, 2010).  
Type I errors (denoted by α) and Type II errors (denoted by β) are normally 
considered serious (Faul, Erdfelder, Buchner, & Lang, 2009; StatPower, n.d.). Type I 
errors occur when a null hypothesis is rejected when it is true, and Type II errors occur 
when a null hypothesis fails to be rejected when the alternative hypothesis is true 
(McCrum-Gardner, 2010). For this analysis, because both types of errors are equally 
serious, the β/α ratio was set at 1 rather than some other value like 2, which signifies that 
a researcher is 2 times more likely to commit a Type II error over a Type I error. Based 
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on the conditions for a compromise power analysis (N = 1,592, β/α ratio = 1, OR = 1.68, 
a two-tailed binomial test), I estimated power to be 0.981. This power estimate was 
adequate to detect a significant relationship between insurance coverage, the type of 
medical facility accessed for health care, and HPV vaccine completion, assuming that 
such significance existed. 
Access to the Data Set 
 NIS-Teen data sets are publicly available. Data sets for public use can be 
downloaded from the CDC website. In addition to accessing the data set, users also can 
access and download all documents associated with the data set, including data 
documentation, a codebook, a data user’s guide, a copy of the Household Interview 
Questionnaire that was used to collect the data, and the providers’ immunization history 
questionnaire (CDC, 2016a). Because the data file was released in a format that was 
incompatible with commonly used statistical software, input statements were also 
provided to facilitate the transformation of the data into a format that is compatible with 
the software used to analyze the data (CDC, 2016a).  
 The NIS-Teen data are publicly available, and no special permission is required to 
use them. However, as per the National Center for Immunization and Respiratory Disease 
(NCIRD) and the CDC, users of the NIS-Teen data sets are asked to comply with the 
following statements (CDC, 2016a):  
1. To only use the data files for analysis and statistical reporting. 
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2. If identifying information is inadvertently found, users are prohibited from 
using such information and are asked to contact the NCIRD upon such 
discovery. 
3. Researchers are also prohibited from linking these data files with identifiable 
information with other NCIRD or non-NCIRD data files given respondent.  
Use of the data signified the researcher’s compliance with the aforementioned statements.  
Instrumentation  
  The NIS-Teen is one of the surveys used by the CDC and NCIRD to monitor 
vaccine coverage among adolescents 13 to 17 years of age. After a measles outbreak in 
the early 1990s, the CDC (2016a) began using the NIS to track vaccination coverage in 
the United States. Since 1994, the NIS has been used to monitor vaccine coverage among 
children and adolescents as well as flu vaccination coverage among young children 
(CDC, 2016a). The survey is administered annually through telephone interviews to the 
parents of eligible adolescents in all 50 states, the District of Columbia, and some U.S. 
territories (CDC, 2016a). The NIS-Teen collects and provides the most current 
population-based state and local area estimates of vaccination coverage among U.S. 
adolescents (CDC, 2016a).  
 The survey has two parts: Part 1 collects household information, and Part 2 
collects vaccination information from health care providers (CDC, 2016a). The 
household part of the survey has five sections (CDC, 2016a). Section A, which details 
instructions for the screener or the person conducting the interview; Section B, which 
collects vaccination information for current vaccines recommended for adolescents as 
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well as the flu vaccine; Section C, which collects demographic information; Section D, 
which collects health care provider information, and Section E, which collects 
information related to health insurance (CDC, 2016a). Part 2, the health care provider 
part of the survey, is used to verify vaccination information provided by the parents 
during the telephone interviews (CDC, 2016a). Health care providers are asked to 
complete information about their practices, services provided, and vaccine-related 
information pertaining to the children in question (CDC, 2016a). 
Operationalization of Constructs 
 Insurance coverage was based on the insurance status of eligible Hispanic 
adolescents. Individual insurance status was coded “yes” (1) for having insurance 
coverage and “no” (0) for having no insurance coverage. Adolescents with insurance 
coverage were categorized as having private or public insurance. Being uninsured was 
defined as having no insurance coverage (CDC, 2016a).  
Continuity in health insurance coverage was measured by periods of “no gap” in 
insurance coverage (CDC, 2016b). This included individuals who were currently insured 
and were never uninsured. Discontinuous coverage was measured by periods of “gap” in 
insurance coverage resulting from the loss of private or public insurance coverage. This 
included (a) individuals who were currently insured, but were uninsured at some point; 
and (b) individuals who were currently uninsured, but were insured at some point. This 
group also includes individuals who were currently uninsured and were never insured for 
the period in question.  
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 Type of medical facility used to access health care was assessed as the facilities 
used to access primary care providers. This included public facilities, hospital, private 
practices, school-based clinics, and teen clinics (CDC, 2016b). In this study, the facilities 
were categorized as public facilities such as public health-operated clinics, hospital-based 
clinics, and private practices.  
 Vaccination status was defined as being immunized against HPV by receiving one 
of the three HPV vaccines currently available in the United States (CDC, 2016b). 
Vaccination status was defined operationally as whether or not a girl had been fully 
vaccinated with one of the recommended HPV vaccines, that is, if she had received all 
three doses of the vaccine. A “no” (0) response indicated that the girl had not been 
vaccinated, and a “yes” (1) response indicated that the girl had received at least one dose 
of the HPV vaccine series. 
Data Analysis Plan 
 Secondary data from the 2016 NIS-Teen were analyzed using SPSS v.25 (IBM 
Corporation, 2017). Once the data were downloaded, I reviewed the data set for incorrect 
values, duplicated data, or missing data. To simplify the data set, I deleted all variables 
that were of no relevance to the study. Missing data were coded as such to ensure that 
they were handled appropriately during the analysis. In cases of nonresponses, the 
originator of the NIS-Teen data set imputed values to account for the missing data (CDC, 




  I recoded the variables of interest to the current study to answer the research 
questions. In cases where the variables were nominally scaled, the data were unlikely to 
have outliers; however, for numerical variables (e.g., age and date, if applicable), the data 
were assessed for outliers. As deemed necessary, I removed outliers based on the survey 
question being answered. All statistical analyses were based on weighted data. Statistical 
significance for all statistical tests was based on the standard alpha value (α = 0.05). 
Whether a null hypothesis was accepted or rejected was assessed by the p value. If the p 
value was less than or equal to .05, the null hypothesis was rejected in favor of the 
alternative hypothesis. The research questions and hypotheses were as follows: 
Research Question 1 
Research Question 1: Is there a statistically significant relationship between health 
insurance coverage and the HPV vaccination status of Hispanic girls? 
H01: There is no statistically significant association between health insurance 
coverage and the HPV vaccination status of Hispanic girls.  
Ha1: There is a statistically significant association between health insurance 
coverage and the HPV vaccination status of Hispanic girls. 
 Health insurance status was operationalized as a nominal variable; insurance 
coverage was coded as 1, and no insurance was coded as 0. HPV vaccination status was 
operationalized as a nominal variable; vaccinated was coded as 1, and unvaccinated was 
coded as 0. The data were analyzed in three stages. For the first stage, univariate analysis 
was conducted. At this stage, descriptive statistics of the data were provided. For the 
second stage, bivariate analysis was conducted to assess the association between 
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insurance coverage and HPV vaccination status. This association was assessed using chi-
square tests of association. In addition to chi-square tests, Cramer’s V statistic was 
calculated to measure the strength of the relationship between health insurance coverage 
and completion of the HPV vaccine series. For the third stage, multiple logistic 
regression modeling was used to assess the association between insurance coverage and 
HPV vaccination completion, adjusting for maternal age, family income, maternal 
education, and health care provider recommendations. 
Stepwise regression was used to fit the regression model. Variables were added to 
the model using forward selection, which starts with an empty model (i.e., a model with 
only the constant) and sequentially adds all of the other variables of interest (i.e., the 
independent variables and covariates). The significance of the model was assessed by the 
collective effect of the IV, as represented by χ2 coefficient. The Nagelkerke R2 assessed 
the variability on the dependent variable that was accounted for by the independent 
variable. The Wald coefficient was used to assess the significance of the IV. The 
probability that insurance coverage affected HPV vaccination coverage was determined 
by odds ratio and was interpreted as follow: An odds ratio value greater than 1.0 
indicated an increased chance of completing the HPV vaccine series, and an odds ratio 
value less than 1.0 indicated a decreased chance of completing the vaccine series. 
Research Question 2 
Research Question 2: Is there a statistically significant relationship between the 
type of medical facility used to access health care and the HPV vaccination status of 
Hispanic girls?  
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H02: There is no statistically significant association between the type of medical 
facility used to access health care and the HPV vaccination status of Hispanic girls.  
Ha2: There is a statistically significant association between the type of medical 
facility used to access health care and the HPV vaccination status of Hispanic girls. 
 Logistic regression was used to assess the extent to which the type of medical 
facility used to access health care affected completion of the HPV vaccine series. Type of 
medical facility used to access health care was operationalized as a nominal variable and 
was assessed based on the facility accessed for care, that is, private and public facilities 
or hospital-based clinics. Private facility was coded as 0, public facility was coded as 1, 
and hospital-based clinics were coded as 2. HPV vaccination status also was 
operationalized as a nominal variable; vaccinated was coded as 1, and unvaccinated was 
coded as 0. 
 I analyzed the data in three stages. For the first stage, univariate analysis was 
conducted. At this stage, descriptive statistics of the data were provided. For the second 
stage, bivariate analysis was conducted to assess the association between the type of 
medical facility used to access health care and HPV vaccination status. This was assessed 
using chi-square test of association. In addition to chi-square test, Cramer’s V statistic 
was calculated to measure the strength of the relationship between the type of medical 
facility used to access health care and completion of the HPV vaccine series. For the third 
stage, multiple logistic regression modeling was used to assess the association between 
the type of medical facility used to access health care and HPV vaccination completion, 
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adjusting for maternal age, family income, maternal education, and provider 
recommendation. 
Stepwise regression was used to fit the regression model. Variables were added to 
the model using forward selection. Forward selection starts with an empty model (i.e., a 
model with only the constant) and sequentially adds all the other variables of interest 
(i.e., the independent variables and covariates). The significance of the model was 
assessed by the collective effect of the independent variables as represented by χ2 
coefficient. The Nagelkerke R2 was used to assess the variability on the dependent 
variable that was accounted for the independent variable. The Wald coefficient was used 
to assess the significance of the independent variable. The probability that the type of 
medical facility used to access health care affected HPV vaccination coverage was 
determined by odds ratio and was interpreted as follow: An odds ratio value greater than 
1.0 indicated an increased chance of completing the HPV vaccine series, and an odds 
ratio value less than 1.0 indicated a decreased chance of completing the vaccine series. 
Research Question 3 
Research Question 3: Is there a statistically significant relationship between health 
insurance coverage and the type of medical facility used to access health care, and the 
likelihood of completing the HPV vaccine series?  
H03: There is no statistically significant association between health insurance 
coverage and the type of medical facility used to access health care and the likelihood of 
completing the HPV vaccine series.  
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Ha3: There is a statistically significant association between health insurance 
coverage and the type of medical facility used to access health care and the likelihood of 
completing the HPV vaccine series.  
 Logistic regression was used to test the association between insurance coverage 
and the type of medical facility used to access health care, and HPV vaccination status. 
Health insurance status was operationalized as a nominal variable; no insurance was 
coded as 0, and insurance coverage was coded as 1. Type of medical facility used was 
operationalized as a nominal variable and was assessed based on access to private or 
public facilities and hospital-based clinics. Private facility was coded as 0; public facility 
was coded as 1, and hospital-based clinics were coded as 2. HPV vaccination status was 
operationalized as a nominal variable: unvaccinated was coded as 0, and vaccinated was 
coded as 1. 
 The data were analyzed in three stages. For the first stage, univariate analysis was 
conducted. At this stage, descriptive statistics of the data were provided. For the second 
stage, multivariate analysis was conducted to assess the association between insurance 
coverage and the type of medical facility used to access health care, and HPV vaccination 
status. This was assessed using multiple logistic regressions. For the third stage, multiple 
logistic regression modeling was used to assess the association between insurance 
coverage and the type of medical facility used to access health care, and HPV vaccination 




In the third stage, stepwise regression was used to fit the regression model. 
Variables were added to the model using forward selection, which starts with an empty 
model (i.e., a model with only the constant) and sequentially adds all the other variables 
of interest (i.e., the independent variables and covariates). The significance of the model 
was assessed by the collective effect of the independent variables, as represented by χ2 
coefficient. The Nagelkerke R2 assessed the variability on the dependent variable that was 
accounted for by the independent variables. The Wald coefficient was used to assess the 
significance of the independent variables. The probability that insurance coverage and the 
type of medical facility used to access health care affected HPV vaccination coverage 
was determined by odds ratio and was interpreted as follow: An odds ratio value greater 
than 1.0 indicated an increased chance of completing the HPV vaccine series, and an 
odds ratio value less than 1.0 indicated a decreased chance of completing the vaccine 
series. 
Statistical Assumptions: Chi-Square Test 
 Three key assumptions were made about the data when conducting a chi-square 
test for association. Preliminary investigation of the data was conducted to confirm that 
these assumptions were met. For the first and second assumptions, all of the variables 
used in this study were nominal variables falling into two or more independent categories 
(Laerd Statistics, 2018a). For example, HPV vaccination status had two groups: yes and 
no. The variable insurance coverage had two groups (i.e., insured and uninsured), and 
type of medical facility had three groups (i.e., private, public, and hospital). The variable 
discontinuity in insurance coverage was also consistent with this assumption because it 
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had four groups (insured and never uninsured, uninsured and never insured, currently 
insured but uninsured at some point, and currently uninsured but insured at some point). 
The third assumption (McHugh, 2013) that all expected values should have been greater 
than 5 for at least 80% of the cells included in the contingency table was met because all 
of the expected values were greater than 5 for chi-square tests of association conducted. 
Statistical Assumptions: Multivariate Logistic Regression 
 Several key assumptions are made about the data when conducting a multivariate 
logistic regression (Laerd Statistics, 2018b): (a) The dependent variable should be a 
nominal (i.e., categorical) variable; (b) at least one of the independent variables should be 
categorical (i.e., ordinal or nominal variable) or continuous (i.e., interval or ratio 
variable); (c) the data should have independence of observations and the categories of 
dependent variables and independent variables should be mutually exclusive and 
exhaustive; (d) there should be no correlation or multicollinearity between the 
independent variables; (e) there should be a linear relationship between any continuous 
independent variables and the logit transformation of the dependent variable; and (f) the 
data set should not contain any outliers or highly influential points (Laerd Statistics, 
2018b). Preliminary investigation of the data conducted confirmed that the logistic 
regression assumptions were met. The first and second assumptions were met because the 
dependent variable of HPV vaccine status was a dichotomous variable (yes/no) and the 
independent variables of insurance coverage and type of medical facility were nominal 
variables. There was no relationship between observations in the variables of interest 
because the categories of the dependent variable and independent variables were 
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mutually exclusive and exhaustive, thus satisfying the third assumption. Relative to the 
fourth assumption, the variance inflation factor value for the independent variables 
ranged from 1.007 to 2.862 suggesting moderate multicollinearity. However, because 
these values were below 5, the inclusion of these variables should not affect the 
regression model (Akinwande, Dikko, & Samson, 2015; Vatcheva, Lee, McCormick, & 
Rahbar, 2016). The fifth assumption presumed that there should have been a linear 
relationship between any continuous independent variables and the logit-transformed 
dependent variable. Because the independent variables in this study were nominal 
variables, this assumption was not jeopardized. Lastly, for the sixth assumption, boxplots 
produced by SPSS did not identify outliers in the data set. 
Rationale for Inclusion of Covariates 
 Four covariates were taken into consideration in this study: health care providers’ 
recommendation, maternal age, maternal education, and family income. Adolescents with 
health care providers’ recommendation (Gilkey et al., 2016); higher family income 
(Polonijo & Carpiano, 2013); and other maternal-related socioeconomic indicators (e.g., 
age and education) were more likely than individuals without health care providers’ 
recommendation and individuals with low socioeconomic status to complete the HPV 
vaccine series (CDC, 2016a; Fisher et al., 2013; Polonijo & Carpiano, 2013). Because 
these covariates were associated with reduced uptake of the HPV vaccine series (Fisher et 
al., 2013; Gilkey et al., 2016; Polonijo & Carpiano, 2013), their presence could have 
affected the relationships between the variables being evaluated in this study 
(Pourhoseingholi, Baghestani, & Vahedi, 2012). Consequently, regression models were 
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used to control for any effect that the covariates could have had on the dependent variable 
and the independent variables so that the relationships between the dependent variable 
and the independent variables was not masked by the presence of the covariates.  
Threats to Validity 
External Validity 
  External validity addresses factors within a study that might reduce the 
generalizability of the results (Polit & Beck, 2010). Generalizations can be made from 
samples to target populations, across populations, over time, and to other settings 
(Khorsan & Crawford, 2014). Relative to the current study, generalization of the results 
was limited to the design of the study. The NIS-Teen is a cross-sectional survey; hence, 
the information gathered from the respondents reflected that time period (i.e., 2016). 
Therefore, a study of this nature might not yield the same results a year or even 5 to 10 
years from now. Similarly, the target population in the current study were Hispanic girls 
13 to 17 years of age, so the results could not be generalized to girls 13 to 17 years of age 
from other racial or ethnic groups.  
Another threat to the external validity of this study was the effect of the 
respondents’ awareness that they were participating in a study. Because of this 
awareness, they might have responded in ways based on what they thought were expected 
from them rather than what was true. Hence, their responses might have been different 
from what they would have been in different settings or contexts. 
Internal Validity 
  Internal validity refers to whether the exposure of interest (i.e., discontinuity in 
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insurance coverage or limited access to health care) made a difference on the outcome of 
interest (i.e., HPV vaccination status) and whether there was enough evidence to support 
such a claim (Sullivan, 2011). Inferences made based on the findings of this study could 
have been threatened by the instrument used to measure the variables of interest and by 
interviewer effects. The NIS-Teen and other surveys are conducted by the National 
Opinion Research Center at the University of Chicago under the direction of the CDC 
(CDC, 2016a). The instrument was a pretested, standardized questionnaire that was 
administered by highly trained screeners and interviewers, so threats of this nature were 
minimized (CDC, 2016a).   
 Subject effects also can threaten the internal validity of a study. Because the NIS-
Teen is a cross-sectional survey, it could have been subjected to recall bias because the 
respondents were asked questions about the vaccination status of adolescents in the 
households. The responding parents might have provided information regarding the 
children’s vaccination status that might not have been accurate. With the consent of the 
parents, health care providers were asked to verify the vaccination status of the children. 
In some cases, vaccination status reported by the parents might have been inflated and 
might not have matched the providers’ records. Even though provider-verified 
vaccination information was crucial to estimating vaccine coverage, discrepancies in 
reporting might have gone unresolved because neither health care providers nor parents 
were contacted a second time to resolve such issues.  
Construct Validity 
  Construct validity refers to the extent to which an instrument measures the 
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construct it is intended to measure (Westen & Rosenthal, 2003). Failure to operationalize 
all constructs appropriately can affect the conclusions of any studies. Using a single 
construct results in underrepresentation of the construct, making it difficult to assess the 
real effect of this construct on the outcome of interest (Westen & Rosenthal, 2003). NIS-
Teen data have been used extensively, and as such, researchers have supported the 
robustness of the survey, thus minimizing this threat (CDC, 2016a).  
Ethical Considerations 
 For this study, I used secondary data from the 2016 NIS-Teen that were released 
to the public for research purposes. All identifiable information or characteristics were 
removed from the data files before they were released to the public. The original 
researchers obtained informed consent from the respondent (i.e., the parent, male or 
female) who is most knowledgeable of the adolescents’ vaccination histories. Data 
collectors were bound by a confidentiality agreement and instructions prohibiting 
disclosure of any identifiable information. The data were collected and processed under 
high security and strict confidentiality. The data set was used only for research purposes. 
Because the 2016 NIS-Teen data set was devoid of any personally identifiable 
information, to maintain that confidentiality of the respondents, no attempt was made to 
determine or obtain any of their personal identifiable information (Cohen & Mello, 
2018).  
 Metcalf and Crawford (2016) posited that combining different data sets would 
result in composite pictures of individuals and reveal their identities. Therefore, the data 
set downloaded for this study was not shared with other researchers or combined with 
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other data sets in an effort to avoid the risk of invading the privacy of the respondents 
(Metcalf & Crawford, 2016). To assure the security of the data, they were stored on a 
password-protected external drive that was kept in a safety deposit box (Office of 
Research Integrity, n.d.). The data will be kept for 5 years, after which time they will be 
destroyed appropriately (Office of Research Integrity, n.d.). Before conducting any part 
of this study, formal approval to conduct this study was obtained from Walden 
University’s Institutional Review Board (IRB approval #10-10-18-0538888). 
Summary 
 In this study, I used a quantitative, cross-sectional design to assess the relationship 
between insurance coverage, the type of medical facility used to access health care, and 
completion of the HPV vaccine series by Hispanic girls 13 to 17 years of age. Secondary 
data from 2016 NIS-Teen were used to conduct the study. In Chapter 3, I discussed the 
research design and the rationale for selecting it. The target population was explained. 
The power associated with the sample size available for this study was determined by an 
a priori power analysis using G*Power 3.1. How the constructs of interest were 
operationalized also was discussed. Logistic regression was used to assess the 
significance of the relationship between insurance coverage and the type of medical 
facility used to access health care, and completion of the HPV vaccine series. The chapter 
concluded with a discussion of the factors that could have threatened the validity of the 
study and the ethical procedures that were followed throughout the study. In Chapter 4, I 
present the results of the study. 
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Chapter 4: Results 
Introduction 
The purpose of this quantitative cross-sectional study was to assess the extent to 
which insurance coverage and the type of medical facility used to access health care 
influenced completion of the HPV vaccine series among adolescent Hispanic girls 13 to 
17 years of age. Presented in this chapter is a summary of the 2016 NIS-Teen response 
rates and the representativeness of the sample from which the data were collected. In this 
chapter, I provided a brief description of discrepancies found in data collection, the 
descriptive characteristics of the sample, the results of the analyses conducted to answer 
each research question, and a summary of the overall findings.    
Survey Response Rates 
 The 2016 NIS-Teen response rate of 32.7% was representative of the total 
landline and cell phone numbers sampled (CDC, 2016a). This rate was measured using 
the Council of American Survey Research Organization method for telephone surveys 
(CDC, 2016a). The Council of American Survey Research Organization methods takes 
into consideration the resolution rate for the combined sample (i.e., the number of 
households with working residential telephone or active cell phone numbers, the 
screening completion rate for the combined sample, and the rate of interviews completed 
for eligible households for the combined sample; CDC, 2016a).  
Representativeness of the Sample 
 The NIS-Teen telephone survey was weighted to be representative of all 
adolescents 13 to 17 years of age; weights were added as baseline-sampling and provider-
89 
 
sampling weights (CDC, 2016a). For baseline-sample weights, because both landline and 
cell phone sampling were included in the 2016 NIS-Teen data collected, dual-frame 
weights were added to each adolescent with a completed household interview (CDC, 
2016a). Dual-frame weights were used to reduce any bias associated with incompleteness 
in the landline sampling (CD, 2016a). For provider-sampling weights, weights were 
added to each adolescent with adequate provider data (CDC, 2016a).  
Discrepancies in Data Collection 
 The HPV vaccine series is administered as a three-dose series at baseline (0 
months), 2 months, and 6 months (CDC, 2017). However, upon review of the 2016 NIS-
Teen data, it became evident that some households had reported that the subject of the 
interview received more than the maximum number of doses of the HPV vaccine. 
Similarly, a small percentage of the health care provider-verified HPV vaccine 
information showed that some adolescents had received more than three doses of the 
vaccine. Consequently, I removed cases with more than the required three doses of the 
HPV vaccine series from the data set.  
Results 
Descriptive Characteristics of the Study Sample 
 The 2016 NIS-Teen data file used for this study comprised data from adolescents 
from the United States and selected U.S. territories. The sample comprised 3,744 female 
Hispanic adolescents, representing a total of 2,483,816 (weighted) female Hispanic 
adolescents. The participants ranged in age from 13 to 17 years (M = 14.97 years,  
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SD = 1.399 years). Of the 2,483,816 female Hispanic adolescents who had completed the 
household interview, 64% had received a health care provider recommendation for the 
vaccine, 26% reported that they did not receive a health care provider recommendation 
for the vaccine, and 8% either refused to answer or did not know if the health care 
provider recommended the vaccine (see Table 1). Of the 2,483,816 female Hispanic 
adolescents, 20% had initiated and completed the HPV vaccine series, 10% did not 
complete the vaccine series, and the HPV vaccination status of 70% of the subjects was 
not reported. Of the 2,483,816 female Hispanic adolescents who had completed the 
health insurance module, 39% had health insurance coverage, 4% had no health insurance 
coverage, and 57% of the participants did not respond to this question. Of the 2,483,816 
female Hispanic adolescents who completed the health insurance module, 6% had 
experienced gaps in insurance coverage at some point since the age of 11 years, 35% 
never experienced gaps in insurance coverage, 1% never had insurance, and 58% of the 
respondents did not respond to this question.  
Relative to the type of medical facility accessed for care, cumulatively, 40% of 
the girls in this sample had access to a source of health care, 4% did not identify the 
source of health care, and 56% of participants did not complete this question. As the 
responding parent, 88% of the mothers were at least 34 years old or older and 12% were 
less than 34 years old. Twenty-one percent of the mothers had obtained some level of 
college education, 22% had self-identified as college graduates, 26% had completed high 
school, and 32% had less than 12 years of school. Twenty percent of the mothers reported 
family income greater than or equal to $75,000, 17% had family income between $40,001 
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and $75,000, and 51% had family income less than $40,000. Thirteen percent refused to 
answer or did not know about the family income.  
Table 1 
Descriptive and Demographic Characteristics of the Study Sample 
Variable Category N % 
Age of adolescent (years) 13 483,561 19.5 
 14 526,727 21.2 
 15 542,249 21.8 
 16 441,275 17.8 
 17 490,004 19.7 
Health care provider recommendation Yes 1,586,407 63.9 
 No 636,159 25.6 
 Don’t know/Refused 189,870 7.7 
 Missing 71,380 2.9 
HPV vaccination status Yes 500,294 20.1 
 No 247,783 10.0 
 Missing 1,735,739 69.9 
Insurance status Uninsured 93,491 3.8 
 Insured 966,802 38.9 
 Missing 1,423,523 57.3 
Continuity in health insurance coverage Currently insured but uninsured at 
some point 
90,065 3.6 
 Currently insured, never uninsured 872,269 35.1 
 Currently uninsured but insured at 
some point 
62,839 2.5 
 Currently uninsured, never insured 30,575 1.2 
 Missing 1,428,068 57.5 
Type of Medical Facility Public  176,298 7.1 
 Hospital 85,867 3.5 
 Private 511,621 20.6 
 STD/school/teen clinics/other 
facilities 
37,721 1.5 
 Mixed 177,147 7.1 
 Unknown 96,382 3.9 
 Missing 139,781 56.3 
Maternal age < 34 years  305,169 12.3 
 34-44 years  1,315,619 53.0 
 45 years and older 863,028 34.7 
Family income < $40,000 1,254,271 50.5 
 $40,000-$75,000 417,269 16.8 
 >$75,001 497,456 20.0 
 Don’t Know 200,983 8.1 
 Refused 113,837 4.6 
Mother’s education Less than 12 years 792,662 31.9 
 High school 642,065 25.8 
 Some college 513,532 20.7 




 Results of the Pearson’s chi-square test identified statistically significant 
differences in the number of participants who had completed the HPV vaccine series by 
health insurance coverage status, χ2 (1, n = 715,277) = 552.40, p < .001 (see Table 2). 
This result suggested that girls who were insured were more likely than girls who were 
uninsured to complete the HPV vaccine series. However, the association between health 
insurance coverage and completion of the HPV vaccine was very weak (Cramer’s V = 
.028).  
Table 2 
Contingency Table for Health Insurance Coverage and HPV Vaccination 
Variable Category HPV vaccine up to date Total 
No Yes 
Insurance status Uninsured 22,213 37,372 59,585 
Insured 213,446 442,246 655,692 
 Total 235,659 479,618 715,277 
  
 Table 3 shows that completion of the HPV vaccine series was different for girls 
who had experienced a gap in insurance coverage and girls who had not. Results of the 
Pearson’s chi-square test indicated that this difference was statistically significant, χ2 (1, 
n = 514,276) = 5550.35, p < .001. Although the association between continuity in health 
insurance coverage and completion of the HPV vaccine series was weak, Cramer’s V = 
.104, the results suggested that HPV vaccine series completion was related to continuity 




Contingency Table for Continuity in Health Insurance Coverage and HPV Vaccination  




No gap in insurance coverage 125,508 297,113 422,621 
Yes gap in insurance coverage 38,821 52,834 91,655 
 Total 164,329 349,947 514,276 
 I conducted a chi-square test of association to assess the relationship between the 
type of medical facility accessed for health care and completion of the HPV vaccine 
series. Results of Pearson’s chi-square test indicated a statistically significant difference 
in the percentage of participants who completed the HPV vaccine series by type of 
facility accessed for care, χ2 (2, n = 539,804) = 13903.294, p < .001. This result 
suggested that completion of the HPV vaccine series was significantly associated with 
having access to a health care facility; however, the association between the type of 
medical facility accessed and completion of the HPV vaccine series was small, Cramer’s 
V = .160 (see Table 4).  
Table 4 
Contingency Table for Type of Medical Facility Used to Access Care and HPV 
Vaccination     
 
Variable Category HPV vaccine up to date Total 
No Yes 
Type of medical 
facility 
Public facilities 48,097 82,791 130,888 
Private practice 93,175 48,394 341,569 
Hospitals 33,126 34,221 67,347 
 Total 174,398 365,406 539,804 
 
Research Question 1 and Hypotheses 
Research Question 1: Is there a statistically significant relationship between health 
insurance coverage and the HPV vaccination status of Hispanic girls?  
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H01: There is no statistically significant association between health insurance 
coverage and the HPV vaccination status of Hispanic girls.  
Ha1: There is a statistically significant association between health insurance 
coverage and the HPV vaccination status of Hispanic girls. 
 I included HPV vaccination, health insurance coverage, and the covariates of 
maternal age, maternal education, family income, and health care providers’ 
recommendation in the final regression model. The regression results showed that the 
addition of HPV vaccination status, health insurance coverage, maternal age, maternal 
education, family income, and health care providers’ recommendation significantly 
improved the fit between the final model and the data, χ2 (df = 5, n = 709,274) = 
38752.04, p < .001. The inclusion of HPV vaccination status, health insurance coverage, 
maternal age, maternal education, family income, and health care providers’ 
recommendation in the final model explained between 5.3% (Cox & Snell R2) and 7.4% 
(Nagelkerke R2) of the variance in completing the HPV vaccine series, and the final 
model correctly classified 68.6% of the cases.  
Table 5 is a summary of the logistic regression coefficient beta (B), the Wald 
statistics, the odds ratio, and its 95% confidence interval (CI). Based on Wald statistics, 
the covariates of maternal age, maternal education, family income, and health care 
providers’ recommendation were significantly associated with completing the HPV 
vaccine series (p < .001). After controlling for maternal age, maternal education, family 
income, and health care providers’ recommendation in the final model, Hispanic girls 
who were uninsured were .878 times less likely to complete the HPV vaccine series (B = 
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-.130, OR = .878, 95% CI [.862, .894]) compared to girls who are insured. As family 
income increases, the odds of completing the HPV vaccine decreased by .989 (B = -.011, 
p < .001; OR = .989, 95% CI [.989, .990]), and not having a health care providers’ 
recommendation decreased the odds of completing the HPV vaccine series by .988  
(B = -.012, p < .001; OR = .988, 95% CI [.988, .988]). As maternal age increases, the 
odds of completing the HPV vaccine series increased by 1.0 (B = .024, p < .001;  
OR = 1.025, 95% CI [1.016, 1.033]), and as maternal education increases, the odds of 
completing the HPV vaccine series increased by 1.3 (B = .268, p < .001; OR = 1.308, 
95% CI [1.301, 1.314]). Therefore, I rejected the null hypothesis in favor of the 
alternative hypothesis that there is a statistically significant association between health 
insurance coverage and completion of the HPV vaccine series after controlling for 
maternal age, maternal education, family income, and health care providers’ 
recommendation.  
Table 5 
Logistic Regression Results for Completing HPV Vaccine Series Based on Health 
Insurance Coverage  
 
Variable B SE Wald df Sig. OR 95% CI 
Lower Upper 
Provider recommendation -.012 .000 8398.33 1 .000 .988 .988 .988 
Maternal age .024 .004 36.05 1 .000 1.025 1.016 1.033 
Maternal education .268 .002 12486.71 1 .000 1.308 1.301 1.314 
Family income -.011 .000 12614.82 1 .000 .989 .989 .990 
Uninsured -.130 .009 196.29 1 .000 .878 .862 .894 
 
 To expand on the insurance coverage model, I conducted a stepwise multiple 
logistic regression using forward selection to assess the significance of the relationship 
between continuity in health insurance coverage and completion of the HPV vaccine 
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series among Hispanic girls. The regression results showed that the addition of HPV 
vaccination status, continuity in health insurance coverage, maternal age, maternal 
education, family income, and health care providers’ recommendation to the final model 
improved the fit between the final model and the data, χ2 (df = 7, n = 704,805) = 
53759.14, p < .001. The inclusion of HPV vaccination status, continuity in health 
insurance coverage, maternal age, maternal education, family income, and health care 
providers’ recommendation in the final model explained between 7.3% (Cox & Snell R2) 
and 10.2% (Nagelkerke R2) of the variance in completing the HPV vaccine series, and the 
final model correctly classified 70.5% of the cases.  
Table 6 is a summary of the logistic regression coefficients beta (B), the Wald 
statistics, the odds ratio, and its 95% CI. Based on Wald statistics, maternal age, maternal 
education, family income, health care providers’ recommendation, and continuity in 
insurance coverage were significantly associated with completing the HPV vaccine series 
(p < .001). After controlling for maternal age, maternal education, family income, and 
health care providers’ recommendation, having gaps in insurance coverage significantly 
increased the odds of completing the HPV vaccine series.  
Compared to girls who were uninsured, girls who were currently insured, but had 
been uninsured at some point since 11 years old, were 1.6 times more likely to complete 
the HPV vaccine series (B = .460, p < .001; OR = 1.584, 95% CI [1.529, 1.641]). 
Likewise, girls who were currently uninsured, but had been insured at some point since 
11 years old, were 4.5 times more likely to complete the vaccine series compared to girls 
who were uninsured (B = 1.505, p < .001; OR = 4.505, 95% CI [4.333, 4.684]). 
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Furthermore, girls who were continuously insured were 3.3 times more likely than girls 
who are uninsured to complete the vaccine series (B = 1.205, p < .001; OR = 3.337, 95% 
CI [3.232, 3.446]). Maternal age, maternal education, family income, and health care 
providers’ recommendation were significantly associated with completion of the HPV 
vaccine series. As family income increases, the odds of completing the HPV vaccine 
series decreased by .99 (B = -.010, p < .001; OR = .990, 95% CI [990, .990]), and not 
having a health care provider recommendation decreased the odds of completing the 
vaccine series by .99 (B = -.012, p < .001; OR = .988, 95% CI [.987, .988]). As maternal 
age (B = .032, p < .001; OR = 1.033, 95% CI [1.024, 1.041]) and maternal education 
increases (B = .257, p < .001; OR = 1.293, 95% CI [1.287, 1.299]), the odds of 
completing the HPV vaccine series increased by 1.0 and 1.2, respectively. This result 
provided further evidence to support my rejection of the null hypothesis in favor of the 
alternative hypothesis that there is a statistically significant association between health 
insurance coverage and completion of the HPV vaccine series after controlling for 





Logistic Regression Results for Completing HPV Vaccine Series Based on Continuity in 
Health Insurance Coverage  
 
Variable B SE Wald df Sig. OR 95% CI 
Lower Upper 
Currently insured but uninsured at 
some point since age 11 
.460 .018 652.55 1 .000 1.584 1.529 1.641 
Currently insured and never  
uninsured since age 11 
1.205 .016 5409.65 1 .000 3.337 3.232 3.446 
Currently uninsured but insured at 
some point since age 11 
1.505 .020 5727.82 1 .000 4.505 4.333 4.684 
Mother’s age .032 .004 60.71 1 .000 1.033 1.024 1.041 
Mother’s education .257 .002 11078.88 1 .000 1.293 1.287 1.299 
Family income -.010 .000 9751.79 1 .000 .990 .990 .990 
Provider’s recommendation -.012 .000 8902.02 1 .000 .988 .987 .988 
 
Research Question 2 and Hypotheses 
Research Question 2: Is there a statistically significant relationship between the 
type of medical facility used to access health care and the HPV vaccination status of 
Hispanic girls?  
H02: There is no statistically significant association between the type of medical 
facility used to access health care and the HPV vaccination status of Hispanic girls.  
Ha2: There is a statistically significant association between the type of medical 
facility used to access health care and the HPV vaccination status of Hispanic girls. 
 For this research question, I conducted a stepwise multiple logistic regression 
using forward selection to assess the significance of the relationship between the type of 
medical facility used to access health care and completion of the HPV vaccine among 
Hispanic girls. Relative to the type of health care facility accessed, only categories that 
were significant contributor to the final model were evaluated. The covariates maternal 
age, maternal education, family income, and health care providers’ recommendation 
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included in the final regression model were significantly (p ≤ .05) associated with uptake 
of the HPV vaccines. The regression results showed that the addition HPV vaccination 
status, the type of medical facility accessed, maternal age, maternal education, family 
income, and health care providers’ recommendation to the model significantly support 
the fit between the final model and the data, χ2 (df = 6, n = 534,300) = 47883.08, p < 
.001. However, the addition of HPV vaccination status, the type of medical facility 
accessed, maternal age, maternal education, family income, and health care providers’ 
recommendation to the final model explained between 8.6% (Cox & Snell R2) and 12% 
(Nagelkerke R2) of the variance in completing the HPV vaccine series, and 70% of the 
cases in the final model were correctly classified.  
Table 7 is a summary of the logistic regression coefficients beta (B), the Wald 
statistics, the odds ratio, and its 95% CI. Based on Wald statistics, maternal age, maternal 
education, family income, and health care providers’ recommendation, and the type of 
medical facility accessed were significantly associated with completing the HPV vaccine 
series, p < .001. After controlling for maternal age, maternal education, family income, 
and health care providers’ recommendation, the type of medical facility, that is, whether 
the health care provider was accessible via public facilities (B = .460, p < .001; OR = 
1.584, 95% CI [1.553, 1.617]) or private practice (B = .821, p < .001; OR = 2.273, 95% 
CI [2.233, 2.314]) increased the odds of completing the HPV vaccine series. As maternal 
age (B = .239, p < .001; OR = 1.270, 95% CI [1.258, 1.282]) and maternal education 
increases (B = .095, p < .001; OR = 1.100, 95% CI [1.094, 1.107]), the odds of 
completing the HPV vaccine series increased by 1.2 and 1.1, respectively. However, 
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family income (B = -.013, p < .001; OR = .987, 95% CI [.987, .987]) and health care 
providers’ recommendation (B = -.017, p < .001; OR = .983, 95% CI [.983, .983]) 
decreased the odds of completing the HPV vaccine series. Therefore, I rejected the null 
hypothesis in favor of the alternative hypothesis that there is a statistically significant 
association between the type of medical facility accessed for health care and completion 
of the HPV vaccine series after controlling for maternal age, maternal education, family 
income, and health care providers’ recommendation.  
Table 7 
 
Logistic Regression Results for Completing HPV Vaccine Series Based on Type of 
Medical Facility Used to Access Health Care  
 
Variable B SE Wald df Sig OR 95% CI 
Lower Upper 
Maternal age .239 .005 2506.32 1 .000 1.270 1.258 1.282 
Maternal education .095 .003 1021.60 1 .000 1.100 1.094 1.107 
Family income -.013 .000 13289.29 1 .000 .987 .987 .987 
Provider recommendation -.017 .000 12215.17 1 .000 .983 .983 .983 
Facility type - public .460 .010 1991.12 1 .000 1.584 1.553 1.617 
Facility type - private  .821 .009 8134.15 1 .000 2.273 2.233 2.314 
 
Research Question 3 and Hypotheses 
Research Question 3: Is there a statistically significant relationship between health 
insurance coverage, the type of medical facility used to access health care, and the 
likelihood of completing the HPV vaccine series?  
H03: There is no statistically significant association between health insurance 
coverage, the type of medical facility used to access health care, and the likelihood of 
completing the HPV vaccine series.    
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Ha3: There is a statistically significant association between health insurance 
coverage, the type of medical facility used to access health care, and the likelihood of 
completing the HPV vaccine series.  
 Stepwise multiple logistic regression was conducted to assess the significance of 
the relationship between health insurance coverage, the type of medical facility used to 
access health care and the likelihood of completing the HPV vaccine series among 
Hispanic girls. Relative to the type of health care facility accessed, only categories that 
were significant contributor to the final model were evaluated. The covariates maternal 
age, maternal education, family income, and health care providers’ recommendation 
included in the final regression model were significantly (p ≤ .05) associated with uptake 
of the HPV vaccines. The regression results showed that the addition of the HPV 
vaccination status, health care insurance, the type of medical facility accessed, maternal 
education, maternal age, family income, and health care provider recommendation to the 
final model significantly improved the fit between the model and the data, χ2 (df = 7,  
n = 510,020) = 51595.98 p < .001. The variables in the final model explained between 
9.6% (Cox & Snell R2) and 13.5% (Nagelkerke R2) of the variance in completing the 
HPV vaccine series, and the final model correctly classified 70.1% of the cases.  
Presented in Table 8 is a summary of the logistic regression coefficients beta (B), 
the Wald statistics, the odds ratio, and its 95% CI. Wald statistics showed that after 
controlling for maternal age, maternal education, family income, and health care 
providers’ recommendation, health insurance coverage, more specifically being 
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uninsured, was significantly associated with completing the HPV vaccine series. For girls 
who were uninsured, the odds of completing the HPV vaccine series decreased by .942  
(B = -.060, p < .001; OR = .942, 95% CI [.921, .963]). The type of medical facility used 
to access health care significantly influenced completion of the HPV vaccine series. 
Access to a public health care facility (B = .514, p < .001; OR = 1.672, 95% CI [1.637, 
1.707]) or a private practice (B = .823, p < .001; OR = 2.277, 95% CI [2.235, 2.319]) 
increased the odds of completing the HPV vaccine series by 1.67 and 2.27, respectively. 
Maternal age, maternal education, family income, and health care providers’ 
recommendation significantly impacted completion of the HPV vaccine series. Increases 
in family income (B = -.014, p < .001; OR = .986, 95% CI [.986, .986]) and lack of a 
health care provider recommendation (B = -.018, p < .001; OR = .988, 95% CI [.981, 
.982]), decreased the odds of completing the HPV vaccine series. As maternal age  
(B = .252, p < .001; OR = 1.286, 95% CI: 1.274, 1.299) and maternal education level 
increases (B = .125, p < .001; OR = 1.133, 95% CI [1.126, 1.140]), the odds of 
completing the HPV vaccine series increased. Hence, the null hypothesis was rejected in 
favor of the alternative hypothesis that there is a statistically significant association 
between health insurance coverage, the type of medical facility used to access health care 
and the likelihood of completing the HPV vaccine series after controlling for maternal 





Logistic Regression Results for HPV Vaccination Based on Discontinuity in Health 
Insurance Coverage and Type of Medical Facility Used to Access Health Care 
 
Variable B SE Wald df Sig OR 95% CI 
Lower Upper 
Maternal Age .252 .005 2598.46 1 .000 1.286 1.274 1.299 
Maternal Education .125 .003 1588.93 1 .000 1.133 1.126 1.140 
Family Income -.014 .000 14637.87 1 .000 .986 .986 .986 
Provider Recommendation -.018 .000 13043.45 1 .000 .982 .981 .982 
Facility type – Public .514 .011 2351.63 1 .000 1.672 1.637 1.707 
Facility type – Private .823 .009 7738.53 1 .000 2.277 2.235 2.319 
Insurance Status: Uninsured -.060 .011 28.63 1 .000 .942 .921 .963 
 
 As indicated in Table 9 below, the addition of continuity in health insurance 
coverage to the final model improved the outcome of the relationship between the type of 
medical facility used to access health care and completion of the HPV vaccine series. 
Results suggested that continuity in insurance coverage and the type of medical facility 
used to access health care significantly influenced the likelihood of completing the HPV 
vaccine series. Hispanic girls who were continuously insured were 3.5 times more likely 
to complete the HPV vaccine series (B = 1.263, p < .001; OR = 3.536, 95% CI [3.400, 
3.678]). Similarly, compared to girls who were uninsured, girls who experienced gaps in 
insurance coverage were more likely to complete the vaccine series, whether they were 
currently insured, but were uninsured at some previous point (B = .180, p < .001; OR = 
1.198, 95% CI [1.148, 1.250]), or they were currently uninsured, but were insured at 
some previous point (B = 1.480, p < .001; OR = 4.395, 95% CI [4,198, 4,601]). Access to 
public health care facilities (B = .699, p < .001; OR = 2.011, 95% CI [1.969, 2.055]) or 
private facilities (B = .967, p < .001; OR = 2.654, 95% CI [2.605, 2. 704]) increased the 
odds of completing the HPV vaccine series. Maternal age, maternal education, family 
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income, and health care providers’ recommendation significantly impacted completion of 
the HPV vaccine series. As family income increases (B = -.013, p < .001; OR = .987, 
95% CI [.987, .988]) and without a health care provider recommendation (B = -.020, p < 
.001; OR = .981, 95% CI [.980, .981]), the odds of completing the HPV vaccine series 
decreased. As maternal age (B = .322, p < .001; OR = 1.380, 95% CI [1.366, 1.394]) and 
maternal education increases (B = .099, p < .001; OR = 1.104, 95% CI [1.098, 1.111]), 
the odds of completing the HPV vaccine series increased. The final model was 
statistically significant, χ2 (df = 9, n = 509,014) = 68524.30, p < .001, and it correctly 
classified 75% of the cases. The inclusion of continuity in health care insurance, medical 
facility type, maternal age, maternal education, family income, and health care provider 
recommendation in the final model explained between 12.6% (Cox & Snell R2) and 
17.7% (Nagelkerke R2) of the variance in completing the HPV vaccine series. This 
provided further evidence in support of rejecting the null hypothesis in favor of the 
alternative hypothesis that there is a statistically significant association between health 
insurance coverage, the type of medical facility used to access health care, and the 
likelihood of completing the HPV vaccine series after controlling for maternal age, 





Logistic Regression Results for HPV Vaccination Based on Discontinuity in Health 
Insurance Coverage and Type of Medical Facility Used to Access Health Care 
 
Variable B SE Wald df Sig OR 95% CI 
Lower Upper 
Maternal age .322 .005 4042.633 1 .000 1.380 1.366 1.394 
Maternal education .099 .003 968.31 1 .000 1.104 1.098 1.111 
Family income -.013 .000 11135.20 1 .000 .987 .987 .988 
Provider recommendation -.020 .000 14237.36 1 .000 .981 .980 .981 
Facility type - public .699 .011 4120.07 1 .000 2.011 1.969 2.055 
Facility type - private .976 .010 10429.09 1 .000 2.654 2.605 2.704 
Currently insured but uninsured at 
some point since age 11 
.180 .022 69.17 1 .000 1.198 1.148 1.250 
Currently insured and never 
uninsured since age 11 
1.263 .020 3956.22 1 .000 3.536 3.400 3.678 
Currently uninsured but insured at 
some point since age 11 
1.480 .023 4004.99 1 .000 4.395 4.198 4.601 
 
Summary 
 In this chapter, weighted data from the 2016 NIS-Teen were evaluated to 
determine the extent to which health insurance coverage and the type of medical facility 
used to access health care influenced the likelihood of Hispanic female adolescents 
completing the HPV vaccine series. In this chapter, I presented the results of the data 
analysis conducted to answer the three research questions. The sample comprised data 
from 3,744 Hispanic female adolescents that were weighted to represent 2,483,816 
Hispanic female adolescents. However, not all survey data were included in the analyses; 
missing data were removed from all statistical analyses.  
Based on the results of the chi-square tests, completion of the HPV vaccine series 
was associated with health insurance coverage and the type of medical facility used to 
access health care. In addition to health insurance coverage, continuity in health 
insurance coverage was significantly associated with completing the HPV vaccine series. 
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The final multiple logistic regression models were used to examine the influence of the 
type of medical facility used to access health care and health insurance coverage on HPV 
completion status showed that the type of medical facility used to access health care and 
health insurance coverage were significantly associated with HPV completion status.  
The key findings were that after controlling for maternal age, maternal education, 
family income, and health care providers’ recommendation, a statistically significant 
relationship was found among completion of the HPV vaccine series, health insurance 
coverage, and the type of medical facility used to access health care. Continuity in health 
insurance coverage improved the likelihood of completing the HPV vaccine series. 
Although Hispanic female adolescents who were uninsured were less likely to complete 
the HPV vaccine series, Hispanic female adolescents who are continuously insured were 
more likely to complete the vaccine series by accessing their health care providers via 
public health care facilities or private practice. Based on the results, the null hypothesis 
that there is no significant association between health insurance coverage and the type of 
medical facility used to access health care, and completion of HPV vaccine series was 
rejected.  
 Included in Chapter 5 is my interpretation of the findings of this study based on 
published research on the effects of health insurance coverage and access to sources of 
health care on HPV vaccine uptake among Hispanic female adolescents. In Chapter 5, I 
discussed the limitations of the study and the implications for positive social change. I 
also provide a detailed description of recommendations for future studies and a 
conclusion to complete the chapter.  
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Chapter 5: Discussion, Recommendations, and Conclusion 
Introduction 
Increasing the completion rate of the HPV vaccine series among Hispanic female 
adolescents has the potential to significantly reduce HPV infections and the prevalence 
and mortality rates of cervical cancer among Hispanic women (Valentino & Poronsky, 
2016). Despite the effectiveness of the HPV vaccines and the ACIP’s recommendations 
to vaccinate female adolescents, HPV vaccine coverage rates remain low among Hispanic 
female adolescents (Jeudin et al., 2014; Markowitz et al., 2014). These low coverage 
rates could be related to inadequate insurance coverage and limited access to health care. 
In this quantitative cross-sectional study, I evaluated the extent to which health insurance 
coverage and access to health care based on the type of medical facility used influenced 
completion of the HPV vaccine series among Hispanic female adolescents. The SEM 
served as the theoretical framework of the study. The understanding gained from this 
study can be used to guide the development of strategies to boost HPV vaccination 
coverage among Hispanic female adolescents.  
 In this study, I evaluated data from the 2016 NIS-Teen to determine the extent to 
which health insurance coverage and the type of medical facility used to access health 
care influenced the likelihood of Hispanic female adolescents completing the HPV 
vaccine series. The results of Pearson’s chi-square tests showed that completion of the 
HPV vaccine series was significantly associated with health insurance coverage and the 
type of medical facility used to access health care. Likewise, continuity in health 
insurance coverage was significantly associated with completing the HPV vaccine series. 
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Further analyses using stepwise multiple logistic regression showed that after controlling 
for maternal age, maternal education, family income, and health care providers’ 
recommendation, completion of the HPV vaccine series was significantly associated with 
health insurance coverage; more specifically, there was a significant association between 
being uninsured and completing the HPV vaccine series.  
Interpretation of the Findings 
 For children from ethnic or racial minorities, Smits-Seemann et al. (2016) found 
that gaps in health insurance coverage for any period were associated with either casual 
use of or a lack of a usual source of preventive care. However, in the current study, gaps 
in insurance coverage did not adversely affect the completion of the HPV vaccine series 
by Hispanic female adolescents. Results of multiple logistic regression showed that gaps 
in insurance coverage since age 11 years significantly increased the likelihood of 
Hispanic female adolescents completing the vaccine series. This result contradicted 
Cowburn et al.’s (2014) findings that although there was no association between 
insurance coverage and completion of the vaccine series, study participants who were 
uninsured for some time were unlikely to initiate the HPV vaccine series. The differences 
in association could have been attributed to one of many factors, including, but not 
limited to, sampling weights used in the current study and bias in the analyses because of 
missing data. The pattern of missing data can substantially result in over- or 
underestimation of the odds of completing the HPV vaccine series based on gaps in 
insurance coverage. In this analysis, it is possible that the odds ratio for HPV vaccine 
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series completion based on gaps in insurance coverage was overestimated, and therefore, 
the results were biased away from the null hypothesis. 
  Results of the multiple logistic regressions showed that there was an association 
between the lack of health insurance coverage and completion of the HPV vaccine series. 
More specifically, being uninsured decreased the likelihood of Hispanic female 
adolescents completing the HPV vaccine series. Conversely, continuous health insurance 
coverage increased the likelihood of Hispanic female adolescents completing the HPV 
vaccine series. This result confirmed the findings of Reiter et al. (2014), who found that 
when compared to Hispanic female adolescents who were insured, those who were 
uninsured were less likely to comply with all vaccine requirements, including completion 
of the three-dose HPV vaccine series. 
Jeudin et al. (2014) identified the lack of insurance as a barrier to HPV 
vaccination for girls from ethnic or racial minorities, including Latina girls, who were 
less likely to complete the vaccine series. Using data from the 2015 NIS-Teen, Lu et al. 
(2018) also showed that, after adjusting for confounding factors, coverage for all 
vaccines, including the HPV vaccine series, was lower among adolescents who were 
uninsured than for adolescents who were insured. Furthermore, De Jesus and Xiao (2014) 
found that continuity in health insurance coverage was predictive of Latinos’ access to 
health care services. Although the results of this study confirmed that a lack of insurance 
coverage negatively influences the completion of the HPV vaccine series, the low rate of 
vaccine completion noted undermined the overall impact of health insurance coverage on 
completing the vaccine series. Likewise, although continuous health insurance coverage 
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was essential to completing the vaccine series, the high percentage of missing values on 
the variables of interest also undermined its impact on completing the vaccine series. 
 Researchers have concluded that compared to other racial and ethnic groups in the 
United States, Hispanics are less likely to use preventive care services (Gelman et al., 
2013; Polonijo & Carpiano, 2013; Velasco-Mondragon et al., 2016). Because Hispanics 
have less access to preventive care services or have no access at all, they are more likely 
to be underimmunized (Gelman et al., 2013). However, the results of this study did not 
support this finding. Instead, the results showed that Hispanic female adolescents with 
access to a source of care, whether private or public, have increased odds of completing 
the HPV vaccine series. This result was consistent with the findings reported by Test et 
al. (2013) that girls with permanent medical homes were more likely to be vaccinated.  
Although access to a health care facility can include hospitals, school-based 
clinics, and other health care facilities, these facilities were excluded from all statistical 
analysis in this study, so their contributions to increasing the rate of HPV vaccine uptake 
could not be ascertained. Furthermore, the results of this study confirmed that having 
access to a source of health care increased the likelihood of Hispanic female adolescents 
completing the HPV vaccine series. However, the high percentage of missing values on 
the variable used to assess the type of medical facility used to access health care 
minimized the ability to assess the overall impact of the source of health care on 
completing the HPV vaccine series.  
All of the variables included in the multivariate regression analysis significantly 
affected the ability of the final model to assess HPV vaccine completion. The results of 
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this study indicated that maternal age and maternal education increased the likelihood of 
Hispanic female adolescents’ completing the HPV vaccine series. However, health care 
providers’ recommendation and family income decreased their likelihood of completing 
the HPV vaccine series.  
Researchers have asserted that health care providers’ recommendation is a key 
predictor of being vaccinated against HPV (Brewer et al., 2011; Gilkey et al., 2015, 2016; 
Holman et al., 2014; Reiter, McRee et al., 2013). In previous studies, Hispanic girls were 
found to be less likely to receive a recommendation for the vaccine from their health care 
providers and were less likely to receive the HPV vaccine in the absence of such a 
recommendation (Gilkey et al., 2015, 2016; Morales-Campos et al., 2013). The results of 
my study showed that Hispanic girls are less likely to complete the HPV vaccine series 
without a health care provider’s recommendation; however, they also showed that even 
though more than 60% of the Hispanic female adolescents in the sample had a provider 
recommendation for the vaccine series, only 20% completed the three doses. Therefore, 
according to the findings in my study, it appears that a health care provider’s 
recommendation does not influence the completion of the HPV vaccine series. It is 
probable that the strength of the recommendation may be more influential on completing 
the HPV vaccine series; however, this factor was not assessed in this study (see Kester, 
Zimet, Fortenberry, Kahn, & Shew, 2013). Receiving a recommendation from health care 
providers for the HPV vaccine may be crucial to initiating the vaccine series, but the 
factors affecting the completion of the vaccine series may be different from those 
required to initiate it (Monnat, Rhubart, & Wallington, 2016). Therefore, as I found in 
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this study, the recommendation made by health care providers alone may not be as 
influential on HPV vaccine completion as predicted.  
 Higher family income has been inconsistently associated with HPV vaccine 
completion (Gold et al., 2013; Laz et al., 2010; Polonijo & Carpiano, 2013). However, 
based on the results of my study, higher family income significantly decreased the odds 
of Hispanic female adolescents completing the HPV vaccine series. This finding was 
comparable to the results of Walker et al. (2018). Using data from the 2017 NIS-Teen, 
these authors found that compared to adolescents with family incomes below the poverty 
level, adolescents from families with incomes at or above the poverty level were less 
likely to receive all three doses of the HPV vaccine series (Walker et al., 2018). The 
finding in the current study is comparable to that of at least one group of researchers; 
however, it should be noted that missing values for family income were imputed. Based 
on the values imputed, it is probable that girls from families that had incomes at or above 
the poverty level were less likely to complete the vaccine series.  
 I used the SEM as the theoretical framework of this study. This model posits that 
intrapersonal factors, interpersonal factors, organizational or institutional factors, 
community-related factors, and social factors can influence the risks of a given health-
related outcome, in this case, not completing the HPV vaccine series (see Baral et al., 
2013; Chimphamba-Gombachika er al., 2012; Nyambe et al., 2016). Although not all of 
the factors were evaluated in this study, results showed that maternal education, maternal 
age, and family income (i.e., intrapersonal factors); health care providers’ 
recommendation to get the HPV vaccine series (i.e., interpersonal factors); health care 
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providers’ accessibility (i.e., organizational or institutional factors); and insurance 
coverage (i.e., community-related factors) influenced the likelihood of Hispanic female 
adolescents completing the HPV vaccine series. Although maternal age, maternal 
education, continuous health insurance coverage, and access to a source of health care 
increased the odds of completing the HPV vaccine series, health care providers’ 
recommendation and family income decreased the likelihood of completing the vaccine 
series. A recommendation from a health care provider is likely to increase the odds of 
receiving the HPV vaccine (Gilkey et al., 2015); however, in this study, the lack of such a 
recommendation or a casual recommendation reduced the likelihood of receiving the 
HPV vaccine.  
 The HPV vaccine series is one of the most expensive vaccines currently available 
in the United States (CDC, 2015b), yet individuals covered by public or private insurance 
do not have any financial hindrance to receiving the vaccine. However, for individuals 
who are uninsured, are underinsured, or have experienced gaps in insurance coverage, 
completion of the HPV vaccine series may be problematic (DeVoe et al., 2015; 
Fairbrother et al., 2011). The results of this study confirmed that Hispanic female 
adolescents who were uninsured were less likely than Hispanic female adolescents with 
continuous insurance coverage to complete the vaccine series. However, I found that gaps 
in insurance coverage did not adversely affect completion of the HPV vaccine series. 
More research is needed to establish whether gaps in insurance coverage affect vaccine 
receipt and completion. Overall, the results of my study corroborated the tenets of the 
SEM that different contextual factors influence the risk of a given health-related outcome 
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(see Baral et al., 2013; Lanning et al., 2017; Nyambe et al., 2016; Paat, 2013). Because 
these factors are interconnected, public health guidelines aimed at addressing the low 
uptake of all three doses of the HPV vaccine series should take into consideration 
strategies that will create change on different levels.  
Limitations of the Study 
 I used secondary data from the 2016 NIS-Teen. As a result, the evaluations 
documented in this study were restricted to questions asked in the survey and were 
limited to variables in the NIS-Teen data set. There were high percentages of missing 
values for the variables of interest to the study. Therefore, despite adjustment for 
nonresponses from health care providers and household interviews and households 
without access to telephones or cell phones, the results of the analyses might have been 
biased due to the high percentage of missing values. The analyses described in this study 
used weighted data, so it is possible that the significance of the associations reported was 
overestimated. Missing data can limit the validity of secondary data sources, so given the 
high percentage of missing information on the dependent variable and the independent 
variables evaluated in this study, the results should be interpreted judiciously.  
Recommendations for Future Studies 
 I evaluated insurance coverage and the type of medical facility used to access 
health care in this study to assess the extent to which they affected the completion of the 
HPV vaccine series. Given the low vaccine coverage rate reported in this study, more 
research may be necessary to identify factors that might be more influential in the uptake 
and completion of the HPV vaccine series. In this study, I used secondary data to 
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evaluate the relationship between insurance coverage, gap in insurance coverage, the type 
of medical facility used to access health care, and completion of the HPV vaccine series. 
Hence, the use of instruments more tailored to specifically assessing insurance coverage, 
gaps in insurance coverage, and access to a source of health care relative to HPV vaccine 
completion is recommended. In light of the conflicting findings regarding the effects of 
gaps in health insurance coverage on completion of the HPV vaccine series, further 
research is needed to clarify or reduce any ambiguity surrounding the contradicting 
findings discussed in this chapter.  
Implications for Positive Social Change 
 Improving the uptake rate of the HPV vaccine series by Hispanic female 
adolescents has several implications for positive social change. The cost of the HPV 
vaccine series is one of the greatest barriers to its completion, so the results of this study 
could help to guide the development of effective strategies to increase HPV vaccination 
rates among Hispanic female adolescents by implementing policies that support 
continuity in insurance coverage. Streamlining Medicaid policies to renew coverage can 
minimize periods of no health coverage for adolescents. Where applicable, provisions 
should be made for continued health coverage until renewal conditions are met. Such 
provisions would ensure that Hispanic female adolescents could receive the vaccines 
promptly and complete the vaccine series in a timely manner.  
  In the United States, the prevalence of HPV has decreased since the introduction 
of the HPV vaccines (Markowitz et al., 2016). This reduction has been partially the result 
of adopting various methods designed to raise awareness of HPV, the HPV vaccine 
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series, and HPV-related diseases. Relative to social change in the Hispanic community, 
heightened awareness could boost the receipt and completion of the HPV vaccines series 
by Hispanic female adolescents. Subsequently, this boost in the uptake of the HPV 
vaccine series could help to reduce the risk of HPV infections and the incidence of HPV-
related cancers over time.  
 Each year, public health efforts to prevent cervical cancer save billions of dollars. 
It has been estimated that the United States spends more than 80% of its annual budget to 
treat and prevent cervical cancer (Coyne-Beasley & Hochwalt, 2016). In Texas, for 
example, a state with a high incidence of cervical cancer, within the first year of 
diagnosis, more than $60,000 per patient is spent to treat women with cervical cancer 
(Lairson et al., 2017). Even though the HPV vaccine does not replace cervical cancer 
screening tools and other treatment modalities, completion of the HPV vaccine series not 
only could prevent millions of cases of HPV infections, cervical cancer cases, and HPV-
related deaths but could also decrease the economic burden associated with HPV-related 
diseases. 
Conclusion 
 As the fourth-leading cause of cancer-related morbidity in the United States, 
cervical cancer is preventable through screening and HPV vaccination (ACS, 2017; 
Perkins, Lin, Silliman, Clark, & Hanchate, 2015; Van Dyne et al., 2018; Vu, Yu, 
Awolude, & Chuang, 2018). Screening through Pap testing is effective in detecting 
precancerous lesions; however, a high percentage of Hispanic women diagnosed with 
cervical cancer never had a Pap test (ACS, 2017; Kepka et al., 2015). Compared to 
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women from other racial and ethnic groups, Hispanic women tend to have the highest 
incidence of HPV-related cervical cancer (ACS, 2017). Currently, three HPV vaccines 
are available to girls as young as 9 years of age; however, compared to other developing 
countries and despite the recommendations of the ACIP, uptake of and completion of the 
HPV vaccine series is the lowest in the United States (Rahman, Hirth, & Berenson, 
2017). The completion rate is even lower among Hispanic female adolescents (Jemal et 
al., 2013). Researchers have asserted that despite having the highest rate of initiating the 
HPV vaccine series, Hispanic female adolescents are less likely to complete the vaccine 
series (Chou et al., 2011; Jeudin et al., 2014; Niccolai, Mehta, & Hadler, 2011).  
 From a socioecological perspective, optimizing uptake of the HPV vaccine series 
by Hispanic female adolescents may require a concerted effort (Ferrer, Audrey, et al., 
2015; Lanning et al, 2017). In this study I identified several factors that influenced the 
completion of the HPV vaccine series among Hispanic female adolescents. After 
controlling for maternal age, maternal education, family income, and health care 
providers’ recommendation, the type of medical facility used to access health care was 
significantly associated with completion of the HPV vaccine series. Similarly, health 
insurance coverage and continuity in health insurance coverage were also significantly 
associated with completion of the HPV vaccine series. Gaps in insurance coverage did 
not adversely affect completion of the HPV vaccine series. However, despite the 
significance of the association between the type of medical facility used to access health 
care and health insurance coverage, the low rate of HPV vaccine completion noted in this 
study indicated that the overall impact of these factors on completion of the vaccine 
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series was relatively small. Therefore, although health insurance and a source of health 
care are essential to completing the HPV vaccine series, further research is needed to 
identify other modifiable contextual factors that may be more influential in completing 
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